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The aim of this study was to obtain a recombinant bifidobacteria with 
high β-galactosidase activity through molecular genetic techniques 
and apply it in vitro lactose hydrolysis and in vivo lactose-
intolerance animal experiments. Incidentally, development of a 
selection marker for a food-grade vector for bifidobacteria was 
pursued to enable recombinant bifidobacteria to be used in various 
applications for the human body and food product in the future. 
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Prior to the development of the β-galactosidase over-expressing 
bifidobacteria, a preliminary study to improve the electroporation 
efficiency of bifidobacteria was performed. As a result, the 
electroporation efficiency of B. bifidum BGN4, which was a 
transformation host in my study, was drastically and consistently 
increased from 103 to 105 CFU / ㎍ DNA. The optimized 
electrotransformation conditions were widely applicable to other 
Bifidobacterium species. 
Returning to the main study, to obtain β-galactosidase over-
expressing bifidobacteria, the β-galactosidase gene (G1) was 
cloned from Bifidobacterium longum RD47 (RD47), which is one of 
the bifidobacterial strains with the highest level of β-galactosidase 
activity, with combinations of several bifidobacterial promoters and 
expressed in B. bifidum BGN4 (BGN4). Among the recombinant 
bifidobacteria, BGN4-G1 exhibited the highest β-galactosidase 
level, for which the hydrolytic activity was continuously 2.5 to 4.2 
times higher than that of BGN4 and 4.3 to 9.6 times higher than that 
of RD47. The β-galactosidase activity of BGN4-G1 was 
exceedingly superior to that of any of the other 35 experimental 
lactic acid bacteria. BGN4-G1 could remove 50% of the lactose from 
the whole milk already at 63 h and finally 61% at 93 h. This figure is 
about twice the lactose removal rate of conventional fermented milk. 
The crude enzyme extract containing 50 ㎍ of protein from BGN4-
G1 could remove 51% of the lactose in milk within 2 h. Therefore, it 
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is believed that the purification of G1 from BGN4 by attaching a his-
tag to the gene will have industrial significance, such as using it in 
the production of lactose-free milk or fermented milk. 
Lactose intolerance (LI) is a worldwide issue in terms of public 
health management. Recently, Bifidobacterium species has attracted 
attention as a potential treatment for lactase deficiency. However, 
contradictory results have been reported in previous studies in which 
bifidobacteria were effective for LI or not. I hypothesized that 
bifidobacteria may be effective in alleviating LI, but the reason for 
the contradictory results in the previous studies were due to 
differences in the β-galactosidase activities among Bifidobacterium 
strains used in the experiments. To prove the hypothesis, it was tried 
to verify the effect of β-galactosidase activities of bifidobacteria on 
LI alleviation by feeding post-weaning Balb/c mice with various 
version of Bifidobacterium strains with different β-galactosidase 
activities (β-galactosidase reduced mutant, wild-type and β-
galactosidase over-expressing bifidobacteria). As a result, the LI 
related symptoms such as total number and total weight of feces and 
intestinal motility have been improved according to the increased 
activity of β-galactosidase of bifidobacteria. The LI alleviation 
effect in the BGN4-G1 administration group was greater than that in 
the lactase-treated group and even reached a LI-uninduced level. 
Meanwhile, the stool frequency and total feces weight of the BGN4 
and BGN4-bgr administration groups tended to decrease compared 
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to the untreated group, but no significant difference was found. In the 
case of intestinal motility, in contrast to the BGN4-bgr group, the 
BGN4 administration group was significantly inhibited in intestinal 
motility compared to the untreated group. This suggests that the LI 
alleviation effect is improved as the β-galactosidase activity of the 
bifidobacteria is increased. 
To explore the mechanisms for improved LI according to the β-
galactosidase activity, a gut microbiome analysis was performed from 
the feces of the mice fed BGN4-bgr, BGN4, BGN4-G1 or NS for two 
weeks. As a result, some meaningful results were derived as follows: 
1) The proportion of several microorganisms associated with 
intestinal health tended to be differentiated between the 
Bifidobacterium-fed groups and the untreated group, 2) The 
bifidobacterial proportion in the BGN4-G1 group tended to be 
increased compared to the other Bifidobacterium-fed groups, 3) The 
balance of SCFAs and lactate was differentiated between the 
Bifidobacterium-fed groups and the untreated group, 4) The rates 
for the change in SCFAs and lactate were grouped in a similar pattern 
in the BGN4-G1 and BGN4 groups except for the BGN4-bgr group.  
Because the BGN4-G1 exhibited a significant effect on LI alleviation, 
it is expected that BGN4-G1 can be reproduced with a food-grade 
vector for bifidobacteria, and it will be used as an LI treatment strain. 
However, food-grade vectors for bifidobacteria have not been 
developed yet to my knowledge, so it was decided to develop a 
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selection marker for constructing a food-grade vector for 
bifidobacteria using the superoxide dismutase (SOD) and catalase 
genes from lactic acid bacteria as food grade selection marker. First, 
the SOD and catalase genes were subcloned into pBES2 with 
combinations of bifidobacterial promoters and a terminator and 
transformed into BGN4 to construct BGN4-SK. For the efficient 
selection of transformant using H2O2, the optimal H2O2 concentration 
and exposure time were investigated. As a result, when a bacterial 
mixture of 102 CFU of BGN4-SK and 108 CFU of wild-type BGN4 
was treated with 4 mM H2O2 stress for 2 h, most of the cells were 
dead and only 34 colonies remained, of which 2 colonies were 
identified as BGN4-SK. It suggests that the selection pressure 
induced by H2O2 is suitable for the selection of a few recombinants 
BGN4 among the majority of wild-type BGN4. It is meaningful in that 
the SOD and catalase genes can be a candidate food grade selection 
marker for bifidobacteria. 
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1.1 Properties and structure of the β-
galactosidase 
 
β-galactosidase (EC 3.2.1.23) also known as lactase catalyzes the 
hydrolysis of the terminal β-1, 4-D-galactosyl residues found in 
β-D-galactosides, such as lactose, and releases D-galactose and 
D-glucose as a final product (Kamran et al., 2016; Nguyen et al., 
2015; Yuan et al., 2008). In addition to hydrolysis, some of the β-
galactosidases catalyze the reverse reaction of the hydrolysis called 
transgalactosylation (Maksimainen et al., 2011). β-galactosidases 
are abundant in animals, plants and microorganisms. These enzymes 
are classified as family 2 (GH2) and 35 (GH35). While approximately 
70% of those derived from GH35 are found in plants, those derived 
from GH2 are found primarily in microorganisms (De Alcantara et al., 
2006). Because of their ability for lactose hydrolysis and 
transgalactosylation, β-galactosidase has several main 
technological applications in the food industry: development of 
lactose-removed milk and dairy products, production of galacto-
oligosaccharides during lactose hydrolysis and use as a component 
of tablet-type β-galactosidase products for alleviation of lactose 
intolerant symptoms (Li et al., 2012; Nguyen et al., 2012). For these 
industrial purposes, β-galactosidases are mainly extracted from 
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microbes including Bifidobacterium (Hsu et al., 2007; Møller et al., 
2001) and fungi. The production of β-galactosidase from 
microorganisms is a preferred choice because of the relatively low 
cost of the enzyme and a higher yield. By extension, to safely use 
β-galactosidase in the food industry, the microorganisms producing 
β-galactosidase must be food-grade. In this respect, 
Bifidobacterium is considered to be a good source of β-
galactosidase due to their GRAS (Generally recognized as safe) 
status (Chanalia et al., 2018). 
Although the structure of β-galactosidase varies depending on the 
source of the enzyme (Rosenberg, 2006), β-galactosidase is 
typically a tetramer of four identical polypeptide chains. Within each 
monomer, the constituent amino acids form five well-defined 
structural domains (Juers et al., 2012). One of these five domains 
forms a jelly roll barrel, and the remaining domains are composed of 
fibronectin, β-sandwich and TIM (triose phosphate isomerase)-
type barrel which is the structure of the central domain (Saqib et al., 
2017). In the central domain, there is an active site that forms a deep 
pocket at the C-terminal end of the TIM-type barrel (Juers et al., 
2012). All residues identified by biochemical experiments as being 
important for catalysis are located in or near this pocket. Monovalent 
and divalent cation binding sites including a sodium/potassium site 
and a magnesium site have been identified in the active site (Juers et 
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al., 2001). The activity of the active site is controlled by the 
dissociation of the tetramer into the dimer (Saqib et al., 2017). The 





















Fig. 1.1 The tetrameric structure of β-galactosidase 
Domain 1, blue; Domain 2, green; Domain 3, yellow; Domain 4, cyan; 
Domain 5, red; Na+, green sphere; Mg2+, blue sphere. Lighter and 
darker shading are used to distinguish between equivalent domains 
in different subunits.  





1.2 The role of β-galactosidase in the food 
industry 
 
1.2.1 Removal of lactose from milk  
β-galactosidase has a crucial role in the food industry, especially 
in the dairy industry. Complete removal of lactose in milk using β-
galactosidase is necessary to address the problem of lactose 
intolerance that occurs in about 70% of the world's population. 
Furthermore, this reaction has other benefits in food industry such 
as prevention of lactose crystallization and the increase of sweetness 
(Benavente et al., 2015). There are 2 methods for removing lactose 
from milk: adding the enzyme to milk to make lactose-free milk and 
reacting the milk with lactic acid bacteria to make fermented milk 
products. 
Currently, there are two processes (batch and aseptic) to produce 
lactose-free milk (Harju, 2004; Troise et al., 2016) and β-
galactosidase is used in both processes. A schematic representation 
of the batch and aseptic processes is illustrated in Fig. 1.2, and the 
figure shows the time point at which the enzyme is added in each 
process. The enzymatic hydrolysis of lactose in milk has two 
alternatives: use of immobilized or soluble β-galactosidase. In the 
past, immobilization of β-galactosidase had attracted much 
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attention as a promising method of reducing the cost of the lactose 
hydrolysis due to repeated use of the enzyme for industrial processes 
(Rosenberg, 2006). However, immobilization of β-galactosidase 
has not been used in industrial practice for the production of lactose-
free milk to date, due to issues with the microbial stability of the final 
product (Dekker et al., 2019). For this reason, only soluble β-
galactosidase is currently used in the batch and aseptic processes for 
lactose-free milk production. In the batch process, β-galactosidase 
is added to milk that is not sterilized yet. This process should be 
performed under cooled conditions (typically 4 - 8℃) to prevent 
microbial growth. After the reaction with the enzyme, the milk is 
pasteurized, homogenized and packaged. Because of the cooled 
conditions and the limited incubation time, the batch process requires 
a large amount of β-galactosidase, and the enzymes available in this 
process must have a relatively high hydrolytic activity at a neutral 
pH and low temperature. When the lactose-free milk is produced 
through the batch process, there is an advantage that no residual β-
galactosidase activity remains in the final product because the 
enzyme is inactivated during the pasteurization of the milk (Dekker 
et al., 2019). Meanwhile, in the aseptic process, filter-sterilized β-
galactosidase is added to UHT (ultra-heat treated)-sterilized milk 
just before packaging (Dahlqvist et al., 1977). The packaged milk is 
stored under moderate temperature for approximately 3 days before 
shipping, during which lactose hydrolysis occurs. Because the 
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incubation time and temperature for the aseptic process are higher 
than for the batch process, the aseptic process requires a relatively 
low amount of β-galactosidase. However, there is a weakness that 
process control can not be achieved because the enzyme is only 
active in the milk package; thus, the highest quality β-galactosidase 
should be used for the aseptic process to prevent problems during 
storage (Dekker et al., 2019). 
The lactose content in milk can also be reduced by the fermentation 
of lactic acid bacteria, such as Lactobacillus, Lactococcus and 
Leuconostoc, which have their own β-galactosidase activity. Lactic 
acid bacteria cause the acidification of milk by the production of 
organic acids, mainly lactate. Furthermore, they produce acetate, 
aroma compounds, exopolysaccharides, bacteriocins and several 
enzymes during the fermentation, which enhance the microbial safety 
and shelf life, and improve the texture and sensory profile of the final 
product (Leroy and De Vuyst, 2004). Most fermented milk products 
still contain a significant amount of lactose because lactic acid 
bacteria can only remove about 30% of the lactose in milk on average, 
which can cause problems for lactose-intolerant people when 
consuming these dairy products (Harju et al., 2012). To overcome 
these shortcomings, β-galactosidase is sometimes added together 
with lactic acid bacteria when making yogurt in the food industry. 
Because the pH of the milk fermented by the lactic acid bacteria drops 
below 5.5 within several hours, a large amount of the enzyme is 
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needed when the neutral β-galactosidase is used because the 
enzyme is rapidly inactivated under acidic condition. In the case of 
using the acid stable enzyme, the amount of enzyme required is 
relatively less, but there is a problem in that the enzymes are not 



















Fig. 1.2 A schematic representation of the batch and aseptic 
processes 









1.2.2 Production of galacto-oligosaccharides 
Galacto-oligosaccharides (GOS) are produced by the 
transgalactosylation activity of β-galactosidase during the 
hydrolysis of lactose (Saqib et al., 2017). A schematic process of 
transgalactosylation by β-galactosidase is illustrated in Fig. 1.3. 
The conversion of lactose to GOS by β-galactosidase is regulated 
by competition between hydrolysis and transgalactosylation. 
Transgalactosylation involves intramolecular and intermolecular 
reactions. Intramolecular galactosyl transfer to D-glucose yields 
regio-isomers of lactose and intermolecular galactosyl transfer 
produces GOS with various degrees of polymerization (DP) from 
lactose (Torres et al., 2010). In general, the yield of the GOS 
synthesis can be improved as follows: using micro-aqueous 
conditions; using a highly concentrated lactose solution; modifying 
the enzyme; and removing the final product or inhibitors from the 
reaction mixture (Czermak et al., 2004; Monsan and Paul, 1995). 
Currently, a number of studies have focused on GOS production from 
microorganism-derived β-galactosidases. Because GOS has been 
reported to specifically promote the growth of the Lactobacillus and 
Bifidobacterium species and reduce the number of pathogenic 
bacteria in the human intestine, they are used as prebiotics in the 
food industry (Møller et al., 2001). Nowadays, GOS is used 
extensively in a variety of applications such as alternative 
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sweeteners, cosmetics, soft drinks, infant food, cereals, and 





















Fig. 1.3 General process of transgalactosylation by β-galactosidase 
a, b, and c: 2, 3, 4, 6 (a≠b), indicate the glycosidic linkage position. 
X, galactosyl donor; Y, galactosyl acceptor. 











1.3 The role of β-galactosidase (lactase) in 
lactose intolerance alleviation 
 
Lactose intolerance (LI) is a clinical syndrome characterized by the 
inability to digest lactose due to a deficiency in lactase activity in the 
intestine. Lactase is localized to the brush border of the small 
intestinal enterocytes. It hydrolyzes dietary lactose into glucose and 
galactose for proper absorption. If lactase in the small intestine is 
deficient or absent, unabsorbed lactose in the small intestine is 
passed to the large intestine and fermented by the colonic microflora. 
During fermentation, lactose is converted into gas and short chain 
fatty acids, and lactose itself and the fermentation products of lactose 
osmotically attract fluid into the bowel (Vonk et al., 2012). After the 
consumption of lactose-containing food, the following typical 
symptoms appear in lactose-intolerant people: abdominal pain, 
nausea, diarrhea, flatulence and bloating. The LI symptoms vary from 
individual to individual, depending on the amount of lactose ingested, 
the degree of lactase deficiency, and the form of lactose-containing 
food (Heyman, 2006).  
Lactase deficiency occurs as three main types: primary, secondary, 
and congenital. Primary lactase deficiency is the most common cause 
of LI, accounting for about 70% of the world population. It is caused 
by a gradual decrease of lactase activity in the small intestine with 
15 
 
age (Heyman, 2006). Secondary lactase deficiency results from a 
reduced level of lactase in the small bowel due to malnutrition, cancer, 
diarrhea, inflammatory bowel disease, or other causes of injury to 
the small intestine. It can occur at any age and is a transient issue. 
Congenital lactase deficiency is the most severe and extremely rare. 
A patient with congenital lactase deficiency has a completely reduced 
or deficient lactase activity in the small intestine at the genetic level 
(Nivetha and Mohanasrinivasan, 2017). 
The fundamental treatment for LI is to exclude milk from the diet of 
LI people. However, this approach can lead to severe nutritional 
deficiencies in calcium, phosphorus and vitamins (Montalto et al., 
2006) and may reduce the quality of life due to dietary restrictions. 
As an alternative to this, fermented milk is generally regarded as the 
ideal milk substitute for LI subjects. However, consuming fermented 
milk instead of milk also has a limitation because only about 30% of 
the lactose is reported to be removed from fermented milk products 
(Harju et al., 2012). To overcome the limitations of the dietary 
approach, alternative strategies are emerging, such as the use of 
exogenous β-galactosidase and probiotics for their bacterial β-









Fig. 1.4 Small intestinal metabolism of lactose  
Lactose entering the small intestine (1) is converted to glucose and 
galactose by lactase (2) or probiotics (3). Excess amount of lactose 
is passed to the large intestine (4). 











Fig. 1.5 Colonic metabolism of lactose 
Lactose entering the colon (1) is fermented by the gut microbiota. 
During the fermentation, gasses are generated by the gas-producing 
bacteria (2) and lactate and SCFAs (short chain fatty acids) are 
produced as a fermentation product (3, 4). SCFAs can be absorbed 
by the epithelial cells (5), used by the gut microbiota (6) or excreted 
into the feces (7). 








1.3.1 Exogenous β-galactosidase 
β-galactosidase has been marketed in a tablet form for LI subjects. 
These tablets contain β-galactosidase active at a low pH, which 
enables the enzyme to function in the stomach. It is recommended 
that the tablet should be taken immediately before the consumption 
of lactose-containing food. Previous studies have reported that 
exogenous enzyme alleviates LI symptoms (Medow et al., 1990; 
Xenos et al., 1998). However, taking tablets of exogenous β-
galactosidase is inconvenient because it should be consumed 
whenever eating lactose-containing food and is not very effective 












1.3.2 Endogenous β-galactosidase expressed in 
probiotics 
Probiotics, in particular the Bifidobacterium and Lactobacillus 
species, have received attention as a potential compensation for 
lactase deficiency, and many related clinical trials have been reported 
(Oak and Jha, 2018). The mechanisms by which probiotics exert their 
LI alleviation effect have not been fully revealed but may involve 
expressing their β-galactosidase activity, modifying the intestinal 
pH and positively affecting bowel functions and the gut microbiota 
(He et al., 2008).  
The effects of probiotics on LI can be expected at two levels: 
removal of lactose in lactose-containing foods and in the small 
intestine, and during fermentation in the large intestine. Live 
probiotics in fermented milk products such as yogurt remove lactose 
in the product, and these lactose-reduced products are ingested as 
a milk substitute for LI subjects. Probiotics are usually consumed in 
the form of bacterial powder or in the form contained in fermented 
products. Ingested probiotics can increase the overall lactose 
hydrolysis of the small intestine. The β-galactosidase activity of 
probiotics is usually optimal between pH 6 - 8 in the small intestine. 
However, in the colon, where the pH decreases to 4, bacterial β-
galactosidase activity is limited, and the lactose is more likely to 
remain unfermented. In this case, osmotic pressure is increased by 
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the residual lactose, and symptoms of lactose intolerance are caused 
by this increased osmotic load. The variable ability of the gut 
microbiota to ferment lactose in LI subjects may explain why 
different subjects have different levels of LI symptom (Lomer et al., 
2008). In reality, several studies have shown that the balance of the 
intestinal microflora affects LI alleviation (Kopp-Hoolihan, 2001; 
Masood et al., 2011).  
It has been reported that regular intake of probiotics can reduce LI 
symptom. He T, et al. (He et al., 2008) showed that Bifidobacterium 
longum capsules in yogurt increase the β-galactosidase activity in 
feces and alleviate LI. A mixture of Lactobacillus casei and 
Bifidobacterium breve also improves LI symptoms (Almeida et al., 
2012) and yogurt containing Lactobacillus acidophilus relieved LI 
(Fuller, 1991). Other probiotic strains also have shown advantageous 
effects on lactase deficiency (Hiele et al., 1988; Lin et al., 1993; 
Rabot et al., 2010). However, contradictory results have also been 
reported that probiotics do not alleviate LI. Saltzman JR, et al. 
(Saltzman et al., 1999) observed that Lactobacillus acidophilus 
consumption did not change the breath hydrogen level or LI 
symptoms and Park MJ, et al. (Park et al., 1999) showed 
Bifidobacterium breve supplementation did not alleviate LI. With 
respect to these conflicting results, Kara M. Levri et al. (Levri et al., 
2005) suggested that specific probiotic strains seem to be beneficial 
for lactase deficiency; thus, further researches on specific strains are 
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necessary to elucidate this potential therapeutic relationship. 
Identifying the LI alleviation effects of specific probiotic strains and 
their mechanisms of action through follow-up studies will be of great 




















Table 1.1 Summary of previous clinical trials on LI alleviation effects 
of probiotics 








1.4 Objective of the present research 
 
β-galactosidase also known as lactase is an enzyme which 
catalyzes the hydrolytic process of lactose. Because it can be used 
to lower the amount of lactose in milk for lactose intolerant people or 
prevent lactose crystallization particularly at low temperature, β-
galactosidase is a crucial enzyme in the dairy industry. Furthermore, 
it has been reported that lactose intolerance (LI) symptoms were 
alleviated when β-galactosidase was administered to LI subjects, 
so exogenous β-galactosidases have traditionally attracted much 
attention as a strategy to manage LI subjects and are currently on 
the market. For these industrial purposes, β-galactosidases are 
mainly extracted from microorganisms. The production of β-
galactosidases from microbes is a preferred choice because of a 
higher yield and thus the relatively inexpensive cost of the enzyme. 
By extension, for β-galactosidase to be used safely in the food 
industry, microorganisms producing β-galactosidase should be 
food-grade. From this point of view, bifidobacteria are regarded as 
a good source of β-galactosidase because of their GRAS (Generally 
recognized as safe) status.  
The aim of the present research was to broaden the application 
range of β-galactosidase from Bifidobacterium by developing 
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recombinant bifidobacteria that highly express a Bifidobacterium-
derived β-galactosidase gene and using this recombinant strain in 
various in vitro and in vivo studies. The recombinant bifidobacteria 
were used to efficiently remove lactose in milk and to verify whether 
the Bifidobacterium strains highly-expressing β-galactosidase 





















Improvement of electroporation-mediated 
transformation efficiency for a Bifidobacterium 
















The human intestine is densely populated by as many as 1013 to 1014 
microorganisms (Suau et al., 1999). Most of these are obligate 
anaerobes including the Clostridia and Bacteroidia groups and the 
genus Bifidobacterium. Bifidobacterium is one of the dominant 
organisms in the gut microflora of healthy children and adults 
comprising more than 1% of the total bacterial count (Blaut et al., 
2002; Matsuki et al., 2004a; Matsuki et al., 2004b).    
Bifidobacteria are gram-positive, anaerobic, catalase-negative and 
fermentative bacteria which have beneficial effects on human health 
and diseases including physiological functions, amelioration of 
inflammation, immunological responses and resistance to infection 
(Aoki et al., 2016; Argnani et al., 1996; Jia et al., 2008; Kim and Ji, 
2006; Ku et al., 2016; Lee et al., 2002; Mitsuoka, 1990; Sivan et al., 
2015; Ventura et al., 2009; You et al., 2004). Because of these 
advantages, bifidobacteria are considered to be representative 
probiotics which are defined as live microorganisms that confer a 
health benefit on the host (Sanders, 2008). Therefore, bifidobacteria 
are suitable as genetically engineered bacteria to augment human 
health. However, molecular biological studies on bifidobacteria have 
been limited by the insufficient genetic tools including effective 
transformation methods. Even though electroporation, a highly 
27 
 
efficient transformation method, is used for bifidobacteria, the 
electroporation efficiency of bifidobacteria is usually less than 104 
CFU / ㎍ DNA in previous studies (Argnani et al., 1996; Guglielmetti 
et al., 2007; Park et al., 1999b; Rossi et al., 1996; Sangrador-Vegas 
et al., 2007; Shkoporov et al., 2008). 
This study aimed to improve the electroporation-mediated 
transformation efficiency of bifidobacteria to a reproducibly high 
level. The crucial factors that determine electroporation efficiency 
are the restriction-modification system (R-M system), cell wall and 
cell membrane structure of bacteria. The bifidobacterial 
electroporation conditions were optimized by focusing on these 
factors. In addition, I evaluated whether the optimized electroporation 
methods can be applied to other Bifidobacterium species. To the best 
of my knowledge, this is the first study to use cell wall-weakening 
agents and a cell membrane permeabilizing agent on bifidobacteria to 











2.2 Materials and methods 
 
2.2.1 Bacterial strains and plasmid DNA 
The various species of Bifidobacterium and plasmid used in this 
study are listed in Table 2.1. Bifidobacteria were grown at 37℃ in 
MRS medium (BD Difco™, Sparks, MD, USA) containing 0.05% L-
cysteine∙HCl. 
The shuttle vector pBES2 was used in this study. pBES2 was 
constructed from a cryptic plasmid from Bifidobacterium longum MG1 
ligated to pUC19 and possesses a chloramphenicol-resistance 












Table 2.1 Bacterial strains and plasmids used in this study 
Bacterial strain Source or reference 
Escherichia coli DH5α Lab stock 
Bifidobacterium bifidum BGN4 Isolated from breast-fed infant feces (Park et al., 1999c), Lab stock 
Bifidobacterium bifidum KCTC 3440 Purchased from Korean Collection for Type Culture  
Bifidobacterium bifidum KCTC 3418 Purchased from Korean Collection for Type Culture  
Bifidobacterium breve KCTC 3419 Purchased from Korean Collection for Type Culture 
Bifidobacterium pseudocatenulatum SJ32 Isolated from healthy human feces (Park et al., 1999c), Lab stock 
Bifidobacterium longum RD65 Isolated from healthy human feces, Lab stock 
Bifidobacterium longum RD72 Isolated from healthy human feces, Lab stock 
Bifidobacterium lactis RD68 Isolated from healthy human feces, Lab stock 
Plasmid Characteristics 
pBES2 7.6 kbp, ApR, CmR 
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2.2.2 DNA manipulation 
Plasmid DNA was extracted from Escherichia coli DH5α 
transformants harboring pBES2 with a Plasmid Purification Mini Kit 
(Nucleogen, Gyeonggi-do, South Korea) and methylated in vitro by 
CpG (M.SssI) and GpC (M.CviPI) methyltransferases (NEB, Ipswich, 
MA, USA). The amount of DNA was measured by a Qubit 4 
Fluorometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). To 
identify the plasmid from the transformants, plasmid DNA was 
extracted with a Plasmid Purification Mini Kit (Nucleogen) following 
an initial lysis step. Cells were resuspended in lysis buffer 
supplemented with lysozyme (20 mg / ml) and incubated at 37℃ for 
1 h. The extracted DNA was digested with restriction enzyme XbaI 
(Fermentas, Waltham, MA, USA) and was identified by comparing 
the restriction patterns with the original E. coli derived plasmid DNA. 
 
2.2.3 Preparation of electrocompetent cells 
Overnight cultures in MRS broth containing 0.05% L-cysteine∙HCl 
were diluted into 50 ml of fresh MRS broth supplemented with 0.05% 
L-cysteine∙HCl, 0.2 M sucrose (final concentration) and increasing 
concentrations of NaCl (0.05 - 0.2 M, final concentration) and 
glycine (0.75 - 1.5%, w/v) for some experiments. The inoculated 50 
ml MRS broth with the additives were anaerobically incubated at 37℃ 
until the OD600 reached from 0.2 to 0.7. The bacteria were harvested 
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by centrifugation and washed three times with 40 ml of 
electroporation buffer (0.5 M sucrose and 1 mM ammonium citrate, 
pH 6.0). The final cell pellet was resuspended in 0.5 ml of ice-cold 
electroporation buffer. 
 
2.2.4 Electroporation  
A 0.1-ml of cell suspension was mixed with plasmid DNA and kept 
on ice for 30 min and then transferred to a pre-cooled Gene Pulser 
cuvette (Bio-Rad, Hercules, CA, USA). If necessary, cell 
suspensions mixed with DNA were incubated in the presence of 
ethanol (0.5 – 2%, v/v) for 10 min shortly before the pulse delivery. 
The cuvette was pulsed at various field strengths and parallel 
resistances using the Gene Pulser Xcell Microbial Electroporation 
System (Bio-Rad). Following the electroporation, 0.9 ml of MRS 
broth supplemented with 0.05% L-cysteine∙HCl and 0.2 M sucrose 
(final concentration) was added to the bacteria and incubated at 37℃ 
for 3 h under anaerobic condition. The bacteria were then plated onto 
MRS agar containing 3 ㎍ / ml of chloramphenicol. The plates were 







2.3 Results  
 
To enhance the bifidobacterial electrotransformation efficiency, I 
first chose Bifidobacterium bifidum BGN4 as the experimental strain 
which was isolated from healthy infant. B. bifidum BGN4 has been 
used as a probiotic strain in global food markets since 2001 because 
of its reported benefits. BGN4 exhibits an outstanding colon cell 
adhesive ability among other bifidobacteria (Kim et al., 2003; Ku et 
al., 2009), significant immunoregulatory capacities (Hong et al., 2009; 
Kim and Ji, 2006; Kim et al., 2007; Lee et al., 2002; Lee et al., 2006) 
and anti-cancer effects (Ku et al., 2009; You et al., 2004). These 
features of BGN4 made it as an interesting candidate for the 
development genetically modified version of bifidobacteria.  
In this study, I proceeded with the experiments by applying the 
optimal conditions of the previous step to the next step. The following 
sequence of conditions were investigated: 1) in vitro methylation, 2) 
amount of plasmid DNA, 3) electrical parameters, 4) bacterial growth 
phase, 5) cell wall weakening agent, and 6) cell membrane 
permeabilizing agent. Each step was repeated three times 
independently. The transformation efficiency was expressed as the 
number of transformants per ㎍ of DNA added. Several colonies per 
plate were randomly selected and the plasmid DNA in the 
transformants was identified by comparing the restriction patterns 
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with the original E. coli derived plasmid DNA or by sequencing. 
Results were compared using a nonparametric one-way ANOVA test 
and post-hoc test (Duncan's multiple range test). P<0.05 was 
considered as statistically significant. Because this study aimed to 
develop a high-efficiency electroporation protocol, I adopted the 
experimental method if it showed a consistently high electroporation 
efficiency in all three experiments, even if it was not statistically 
significant.  
 
2.3.1 In vitro methylation 
The restriction-modification (R-M) systems of BGN4 have not 
been studied in detail. It was investigated which commercial 
methyltransferase is the most appropriate to protect against the 
possible R-M system present in BGN4 (Fig. 2.1). GpC methylated 
plasmid DNA was 8 times more effective than the CpG methylated 
one, whereas the untreated one yielded no transformants. Double 
methylated DNA showed no additive effect. This means that BGN4 
has an R-M system which can be effectively avoided by in vitro GpC 
methylation rather than by CpG methylation. Therefore, it was 
decided to use GpC methylated DNA in the next steps of this study. 
The transformation efficiency of pBES2 isolated from BGN4 and GpC 
methylated pBES2 was compared to determine how much GpC 
methylation blocks the R-M systems in BGN4 (Fig. 2.1). pBES2 
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isolated from BGN4 gave a 5.3 fold higher electroporation frequency 
as compared to the corresponding GpC methylated plasmid. As a 
result, GpC methylation does not completely cover the R-M system 
of BGN4, which reflects the fact that in vitro methylation is 










































































Fig. 2.1 Effect of in vitro methylation on the electrotransformation of 
B. bifidum BGN4 
Cells were incubated in MRS broth supplemented with 0.05% L-
cysteine∙HCl and 0.2 M sucrose (final concentration) at 37℃ until an 
OD600 reached 0.4. CpG / GpC / double methylated / untreated plasmid 
DNA (pBES2) or the corresponding plasmid isolated from BGN4 of 
50 ng was added to the competent cell suspension and 
electroporation was conducted under 12.5 ㎸ / cm field strength, 200 
Ω resistance and 25 ㎌ capacitance. Experiments were repeated 
three times independently. All the groups except pBES2 isolatd from 
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BGN4 were analyzed by one-way ANOVA. Result for GpC 
methylated DNA was significantly higher than the results of CpG 



















2.3.2 Amount of plasmid DNA 
Various amounts of plasmid DNA were added to the 
electrocompetent cells to determine the optimal amount of DNA for 
the electroporation. As the amount of DNA increased, the number of 
transformants also tended to increase, but the transformation 
efficiency was not the same (Fig. 2.2.B). The largest number of 
transformants was obtained from the largest amount of DNA (1 ㎍) 
used in this study and the greatest electrotransformation efficiency 
was obtained when 50 ng of plasmid DNA was used. To minimize the 
amount of time and work and maximize the electrotransformation 
efficiency, it was decided to use 50 ng of DNA. Although the standard 
deviation is high, this is the early stage of the optimization; thus, 
many factors that affect the transformation efficiency were not yet 
controlled for, and there are batch-to-batch variations in the 
electroporation process. In addition, because the transformation 
efficiency should be adjusted to 1 ug DNA, as the amount of inserted 
DNA becomes smaller, the standard deviation becomes greater. The 
raw data show that the tendencies between each independent 







       
Amount of  
plasmid 
DNA 














( CFU / ㎍ 
DNA) 
1 ng 1 1,000 0 0 0 0 
50 ng 48 960 10 200 39 780 
100 ng 55 550 12 120 53 530 
500 ng 227 454 54 108 157 314 
















































Fig. 2.2 Effect of amount of plasmid DNA on the 
electrotransformation of B. bifidum BGN4  
Cells were incubated in MRS broth supplemented with 0.05% L-
cysteine∙HCl and 0.2 M sucrose (final concentration) at 37℃ until an 
OD600 reached 0.4. Separately, 1, 50, 100, 500, 1,000 ng of GpC 
methylated plasmid DNA (pBES2) was added to the competent cell 
suspension and electroporation was conducted under 12.5 ㎸ / cm 
field strength, 200 Ω resistance and 25 ㎌ capacitance. Total 
number of transformants (dark bar) and electrotransformation 
efficiency (light bar) were quantified. Experiments were repeated 




2.3.3 Electrical parameters 
The optimization of the electroporation process involves several 
important factors. The three main parameters are the wave form, 
which is the pulse shape, the field strength and the pulse length. The 
field strength is measured as the voltage delivered across an 
electrode gap and presented as the applied voltage divided by the gap 
size of the electroporation cuvette. The pulse length is the duration 
of time that the sample is exposed to the pulse. These parameters 
should be optimized for different species and even strains (Löfblom 
et al., 2007). The optimal electrical condition of B. bifidum BGN4 was 
found by adjusting these parameters. The Gene Pulser Xcell 
Microbial Electroporation System (Bio-Rad, USA) used in my 
laboratory supports three wave forms: a square wave pulse, 
exponential decay wave pulse, and time-constant pulse. Among 
these, the exponential decay wave pulse is routinely used for 
electroporation of bacteria. When it is used, the voltage rises rapidly 
to the peak voltage set then decreases over time. The pulse length 
in an exponential decay wave pulse is called the time constant which 
is not the same as the time-constant pulse and is defined as the time 
required for the voltage of the untruncated pulse to decline to 1 e-1 
(~37%) of the peak amplitude (Löfblom et al., 2007; Shigekawa and 
Dower, 1988). The time constant is modified by adjusting the 
resistance and capacitance values. Hence, the optimum electrical 
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conditions was found by adjusting the field strength and resistance 
while using the exponential decay wave pulse. The effects on the 
transformation efficiency for field strengths of 12.5 and 15 ㎸ / cm 
and resistances between 50 and 600 Ω were evaluated. The best 
efficiency was obtained under a field strength of 15 ㎸ / cm and a 
resistance of 200 Ω, which is approximately 2 times higher than that 
of the existing conditions used in the laboratory with a field strength 
















Table 2.2 Effect of electrical parameters on the electrotransformation of B. bifidum BGN4.  
Cells were incubated in MRS broth supplemented with 0.05% L-cysteine∙HCl and 0.2 M sucrose (final concentration) 
at 37℃ until an OD600 reached 0.4. GpC methylated plasmid DNA (pBES2) of 50 ng was added to the competent cell 
suspension and electroporation was conducted under indicated field strength and resistance at 25 ㎌ capacitance. 
Experiments were repeated three times independently. 
Field strength 
(㎸ / cm) 
 
Resistance (Ω) 
50 100 150 200 300 400 500 600 
12.5 
Time constant (mS) 1.3 2.6 3.6 4.7 5.2 6.2 7.7 7.9 
Transformation efficiency 
(transformants / ㎍ DNA) 
387 533 160 2,680 2,330 113 2,040 987 
15 
Time constant (mS) 1.3 2.5 3.7 4.7 6.5 7.9 8.5 9.8 
Transformation efficiency 
(transformants / ㎍ DNA) 
1,040 2,350 3,540 4,810 2,290 607 53 40 
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2.3.4 Bacterial growth phase 
The effects of the bacterial growth phase on the transformation 
efficiency was investigated. Overnight-grown BGN4 were 
inoculated into 50 ml of MRS broth supplemented with 0.05% L-
cysteine∙HCl and 0.2 M sucrose (final concentration) and cultured 
until the OD600 reached from 0.2 to 0.7. when the OD600 was 0.4 
(early-exponential phase), the transformation frequency was 
notably increased, which is 2.9 times higher than the second highest 
efficiency of OD600 0.3 and 15 times higher than the lowest efficiency 












































Fig. 2.3 Effect of bacterial growth phase on the electrotransformation 
of B. bifidum BGN4  
Cells were incubated in MRS broth supplemented with 0.05% L-
cysteine∙HCl and 0.2 M sucrose (final concentration) at 37℃ until an 
OD600 reached from 0.2 to 0.7. GpC methylated plasmid DNA (pBES2) 
of 50 ng was added to the competent cell suspension and 
electroporation was conducted under 15 ㎸ / cm field strength, 200 
Ω resistance and 25 ㎌ capacitance. Experiments were repeated 
three times independently. Result for OD600 0.4 was statistically 




2.3.5 Cell wall weakening agent 
 Cell wall weakening agents were added to the medium to investigate 
their effects on the electroporation efficiency. Glycine has been 
frequently shown to increase the electroporation efficiency in some 
bacteria (Gerber and Solioz, 2007; Hashiba et al., 1990; Holo and Nes, 
1989; Kim et al., 2005; Pyne et al., 2013; Thompson and Collins, 
1996), and NaCl was used in one study  (Palomino et al., 2010). 
Based on this, glycine and NaCl were each tested to determine 
whether these additives enhance the electroporation efficiency of B. 
bifidum BGN4. The highest glycine and NaCl concentrations were 
selected as 1.5% and 0.2 M, respectively, to minimize the inhibition 
of the bacterial growth and the experiments were performed at lower 
concentrations accordingly. When 0.2 M NaCl was used to treat the 
cells, an approximately 20-fold increase in the electroporation 
frequency was obtained compared to the control without any 
treatment (Fig. 2.4.B).  However, glycine, already known to be 
effective for several bacteria, did not enhance transformation in this 































































Fig. 2.4 Effect of cell wall weakening agents on the 
electrotransformation of B. bifidum BGN4 
Cells were incubated in MRS broth supplemented with 0.05% L-
cysteine∙HCl, 0.2 M sucrose (final concentration) increasing 
concentrations of NaCl (0 – 0.2 M, final concentration) or glycine (0 
– 1.5%) at 37℃ until an OD600 reached 0.4. GpC methylated plasmid 
DNA (pBES2) of 50 ng was added to the competent cell suspension 
and electroporation was conducted under 15 ㎸ / cm field strength, 
200 Ω resistance and 25 ㎌ capacitance. A. Investigation of glycine 
concentrations. B. Investigation of NaCl concentrations. Experiments 
















2.3.6 Cell membrane permeabilizing agent  
Finally, it was investigated whether ethanol which is known to be 
effective with some species of bacteria (Assad‐García et al., 2008; 
Pyne et al., 2013; Sharma et al., 2007) improves the 
electrotranformation efficiency by altering the properties of the cell 
membrane. Because ethanol tolerance varies depending on the strain 
(Gold et al., 1992), the tolerance of B. bifidum BGN4 was examined 
by inoculating this strain with MRS medium containing various 
concentrations of ethanol. Because the growth of BGN4 was 
considerably retarded at above 2% (v/v) ethanol, the effect of ethanol 
on the electroporation efficiency was investigated at lower 
concentrations. Ten minutes prior to the electroporation, ethanol was 
added to a cell-DNA suspension. In the ethanol-treated groups, the 
electroporation efficiency generally tended to be higher than that in 
the untreated group. Among them, the 2% ethanol-treatment 
provided a 1.7-fold increase in the electroporation efficiency 
compared with the no ethanol treatment (Fig. 2.5).   
During this study, the conditions for electroporation-mediated 
transformation of Bifidobacterium were optimized. The optimized 
conditions drastically improved the electrotransformation efficiency 
from 103 to 105 which is about a 72-fold increase from the existing 
conditions in my laboratory (Table 2.3). The differences between the 
initial method and the optimized method are the use of cell wall 
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weakening agent and cell membrane permeabilizing molecule and the 
electrical parameter change, thereby these factors are key points to 
increase the electroporation efficiency of BGN4. Among them, using 
the optimization scheme employed herein, the cell wall weakening 
mediated by NaCl is the most significant factor, which improves the 
electroporation frequency by 20 times. In order to identify whether 
these methods can be applied to other Bifidobacterium species, two 
B. bifidum strains, B. breve, B. pseudocatenulatum, two B. longum 
strains and B. lactis were assayed. As a result, the electroporation 
efficiencies increased from 2.5 to 14 times as compared with the 
initial method and the transformants appeared in all tested species 



































Fig. 2.5 Effect of cell membrane permeabilizing agent on the 
electrotransformation of B. bifidum BGN4 
Cells were incubated in MRS broth supplemented with 0.05% L-
cysteine∙HCl, 0.2 M sucrose (final concentration) and 0.2 M NaCl 
(final concentration) at 37℃ until an OD600 reached 0.4. GpC 
methylated plasmid DNA (pBES2) of 50 ng was added to the 
competent cell suspension and the DNA-cell suspensions were 
supplemented with 0.5, 1, 1.5 or 2% ethanol (v/v) ten minutes prior 
to pulse delivery. Electroporation was conducted under 15 ㎸ / cm 
field strength, 200 Ω resistance and 25 ㎌ capacitance. 
Experiments were repeated three times independently.
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Condition Initial method Optimized method 
Bacterial growth phase OD600 0.4 OD600 0.4 
Cell wall weakening agent added to medium  - 0.2 M NaCl 
Amount of plasmid DNA 50 ng 50 ng 
Types of DNA methylation GpC methylation GpC methylation 
Cell membrane permeabilizing agent  
added to cell-DNA suspension 
- 2% Ethanol 
Electrical parameters  12.5 ㎸ / cm, 25 ㎌, 200 Ω 15 ㎸ / cm, 25 ㎌, 200 Ω 
Transformation efficiency (CFU / ㎍ DNA) 2.04 x 103 1.46 x 105 
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Table 2.4 Comparison of electroporation efficiency of other Bifidobacterium species between initial and optimized 
method 
Bacterial strain 
Initial method Optimized method 
Transformation efficiency  
(CFU / ㎍ DNA) 
Transformation efficiency  
(CFU / ㎍ DNA) 
B. bifidum KCTC 3440 1.3 ± 1.2 x 101  3.3 ± 2.3 x 101  
B. bifidum KCTC 3418 0 1.4 ± 0.7 x 102  
B. breve KCTC 3419 0 7.3 ± 2.3 x 101  
B. pseudocatenulatum SJ32 0.7 ± 1.2 x 101  1.0 ± 0.4 x 102  
B. longum RD65 0 1.3 ± 1.2 x 101 
B. longum RD72 2.0 ± 1.7 x 101 8.7 ± 5.0 x 101 







Electroporation-mediated transformation is generally more 
efficient than chemotransformation and is widely used for gram-
positive and gram-negative bacteria (Itoh et al., 1994; Iwasaki et al., 
1994; Wirth et al., 1989). The average electroporation efficiency is 
104 - 105 CFU / ㎍ DNA and even up to 1010 CFU / ㎍ DNA for E. 
coli (Aune and Aachmann, 2010; Dower et al., 1988; Hanahan et al., 
1991). However, bifidobacteria are vulnerable to oxygen and have a 
multilayered and complex cell wall (FISCHER et al., 1987) as well as 
restriction-modification systems making it difficult to acquire a high 
electroporation efficiency (Serafini et al., 2012). Indeed, the 
electroporation efficiency of bifidobacteria was usually less than 104 
CFU / ㎍ DNA in previous studies (Argnani et al., 1996; Guglielmetti 
et al., 2007; Park et al., 1999b; Rossi et al., 1996; Sangrador-Vegas 
et al., 2007; Shkoporov et al., 2008). Such a lack of efficient 
transformation methods has limited molecular-level studies and 
food-grade vector development of bifidobacteria. Therefore, I 
focused on finding highly efficient electroporation protocols for 
bifidobacteria in this study. First, a suitable strain of bifidobacteria 
which accepts plasmid DNA was chosen. B. bifidum is predominant in 
the gut population of healthy breast-fed infants (Milani et al., 2013; 
Turroni et al., 2012). Because it colonizes initially the infantile 
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intestine, B. bifidum exists widely among the intestinal bifidobacterial 
population in healthy adults (Ku et al., 2016; Turroni et al., 2014). 
Among these bacterial strains, B. bifidum BGN4 originates from the 
feces of a breast-fed infant and is widely used as a probiotic strain 
in global food markets because of its reported benefits (Hong et al., 
2009; Kim et al., 2003; Kim and Ji, 2006; Kim et al., 2007; Ku et al., 
2009; Lee et al., 2002; Lee et al., 2006; You et al., 2004). In this 
respect, it was decided to use B. bifidum BGN4 as the experimental 
strain. 
The important factors determining the electroporation efficiency are 
the R-M system, cell wall and cell membrane of a bacteria, so I 
focused on them. At first, there was an attempt to overcome the R-
M systems of BGN4. R-M systems of several Bifidobacterium sp. 
have been determined by classical restriction analysis (Hartke et al., 
1996; Khosaka et al., 1983; Khosaka et al., 1982; Kim et al., 2010; 
O'Connell Motherway et al., 2009) and by methylome analysis 
generated by single molecule real-time (SMRT) sequencing 
(Bottacini et al., 2017; Mary et al., 2014; O’Callaghan et al., 2015). 
However, the R-M systems of BGN4, even B. bifidum, have not been 
studied in detail to my knowledge. There are various strategies to 
block the R-M system of a transformation host: in vitro methylation 
using methyltransferases, in vivo methylation by expressing 
methyltransferase genes in E. coli, and removal of specific plasmid 
sites recognized by RM systems (Suzuki, 2012). In vitro methylation 
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using methyltransferases, the most convenient method, was 
attempted and it was found that the R-M system of BGN4 was 
effectively blocked by GpC methylation. GpC methylated plasmid 
DNA was 8 times more effective than the CpG methylated one, 
whereas the untreated one yielded no transformants. Double 
methylated DNA showed no additive effect (Fig. 2.1). This means 
that the R-M system of BGN4 is largely affected by in vitro GpC 
methylation rather than by CpG methylation. The transformation 
frequency of pBES2 isolated from BGN4 and GpC methylated pBES2 
was compared to determine how much GpC methylation blocks the 
R-M systems in BGN4. There was a 5.3 fold higher electroporation 
efficiency for pBES2 isolated from BGN4 compared to the 
corresponding GpC methylated plasmid (Fig. 2.1). As a result, 
because GpC methylation does not completely cover the R-M 
systems of BGN4, applying additional in vitro adenine methylation or 
in vivo methylation by expressing methyltransferase genes in E. coli 
is expected to yield a higher efficiency. The putative R-M systems 
in BGN4 were additionally analyzed through the REBASE website 
(http://rebase.neb.com/rebase) using the genome sequence of BGN4. 
Notably, the majority of the predicted recognition sites include the 
sequence where CpG methylation could work rather than GpC 
methylation. This is in contrast to the result shown in Fig. 2.1. Among 
the putative R-M systems of BGN4, there are several systems in 
which the recognition sequence is not predicted. I cautiously suppose 
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that these less predicted R-M systems have a recognition site where 
GpC methylation can act and are relatively active in BGN4. To clarify 
this, it will be necessary to perform a methylome analysis of BGN4 
through single molecule real-time (SMRT) sequencing. 
The initial electrical parameters which were the field strength and 
the resistance were next adjusted. The electroporation efficiency 
nearly doubled when the field strength was increased from 12.5 to 
15 ㎸ / cm at 200 Ω (Table 2.2), which is consistent with the 
studies that higher electric field strengths resulted in greater 
transformation efficiencies for Campylobacter jejuni (Miller et al., 
1988) and for bifidobacteria (Argnani et al., 1996; Serafini et al., 
2012) as long as the lethality does not exceed the threshold level. 
High-voltage pulses during electroporation are likely to destabilize 
the cell walls of gram-positive bacteria (Pyne et al., 2013; Trevors 
et al., 1991). Indeed, the electroporation efficiency tended to 
increase overall at 15 ㎸ / cm than at 12.5 ㎸ / cm at resistances 
ranging from 50 to 400 Ω. However, once the resistance was 500 Ω 
or above which means the time constant is increased by that much, 
the efficiency was the opposite because of the excessive lethality 
(Table 2.2). 
The electroporation efficiency is largely dependent on the structure 
and density of the cell wall (Aune and Aachmann, 2010); thus, 
increasing the fragility of the cell wall by using cell wall weakening 
agents usually improves the transformation efficiency (Gerber and 
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Solioz, 2007; Hashiba et al., 1990; Holo and Nes, 1989; Kim et al., 
2005; Palomino et al., 2010; Pyne et al., 2013; Thompson and Collins, 
1996). In this study, glycine and NaCl were used as the cell wall 
weakening agents. The mechanisms by which these additives weaken 
the cell wall are somewhat different. Glycine replaces D- and L-
alanine residues in peptidoglycan layers, weakening the cell wall due 
to reduction of cross-linking (Hammes et al., 1973). NaCl reduces 
peptidoglycan interpeptide bridges probably by interfering with the 
glycine addition process during peptidoglycan synthesis and results 
in loose cross-linking of the cell wall (Palomino et al., 2009; 
Vijaranakul et al., 1995). A limitation of using these agents is that 
they can be toxic to the cells depending on the species and strain 
(Aune and Aachmann, 2010). Therefore it is critical to find the 
optimal concentration of these additives to increase the 
electroporation efficiency without inhibiting the cell growth. Glycine 
and NaCl were added to the extent that they did not completely inhibit 
the cell growth, and NaCl, rather than glycine, worked well in 
increasing transformation frequency in BGN4 (Fig. 2.4). Although 
glycine is a widely used substance for increasing the electroporation 
efficiency of gram-positive bacteria, it did not increase the 
frequency in BGN4 at all. On the other hand, the use of NaCl as a cell 
wall weakening agent in electroporation has been reported rarely but 
it was effective for bifidobacteria. Because the structure of the cell 
wall is different for each species and strain, empirical screening for 
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the type and concentration of a cell wall weakening agent suitable for 
the bacteria used in the experiments is necessary. 
The cell membrane also acts as a physical obstacle during 
electroporation (Pyne et al., 2013). It has been reported that the 
addition of ethanol to cells increases the efficiency of electroporation 
(Assad‐García et al., 2008; Pyne et al., 2013; Sharma et al., 2007). It 
is well known how ethanol acts on the cell membrane. Ethanol binds 
to the lipid-water interface of the phospholipid bilayers and weakens 
the hydrophobic barrier of the membrane, thereby increasing the 
fluidity and pore size of it (Barry and Gawrisch, 1994; Baskaran et 
al., 1995; Ingram, 1986; Weber and de Bont, 1996). Because ethanol 
is also toxic to cells at certain concentrations and ethanol tolerance 
varies depending on the strain, the minimum inhibitory concentration  
(MIC) of ethanol against BGN4 was first examined. Because BGN4 
growth was inhibited at an ethanol concentration above 2% (v/v), the 
effect of ethanol on the electroporation efficiency was investigated 
at lower concentrations. Though it is not as dramatic as the cell wall 
weakening agent, the permeabilization of the cell membrane with 
ethanol slightly increased the electroporation efficiency (Fig. 2.5).  
 As a result, the electroporation-mediated transformation 
efficiency of B. bifidum BGN4 increased from 103 to 105 CFU / ㎍ 
DNA (Table 2.3). The optimized electrotransformation conditions 
were extensively applied to other Bifidobacterium species; two B. 
bifidum strains, B. breve, B. pseudocatenulatum, two B. longum 
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strains and B. lactis. The electroporation efficiencies increased from 
2.5 to 14 times as compared with the initial method and the 
transformants appeared in all tested species even the species which 
were not transformed under the initial method (Table 2.4). The 
differences between the initial method and the optimized method are 
the cell wall weakening agent and cell membrane permeabilizing agent 
treatment and the electrical parameter change, thereby these factors 
are key points to increase the electroporation efficiency of all tested 
Bifidobacterium species. To the best of my knowledge, this is the 
first study to apply cell wall-weakening agents and a cell membrane 
permeabilizing agent to bifidobacteria to enhance the electroporation 
efficiency. It is expected that further optimizing the concentrations 
of the additives in these newly optimized electroporation conditions 
considering the diversity of the cell walls and membrane structures 
of the Bifidobacterium strains would contribute to improvement of 
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β-galactosidase (lactase, EC 3.2.1.23) catalyzes the hydrolytic 
process of the terminal β-1,4-D-galactosyl residues found in β-
D-galactosides, such as lactose, and releases D-glucose and D-
galactose as an end product (Kamran et al., 2016; Nguyen et al., 2015; 
Yuan et al., 2008). Because it can be used to lower the amount of 
lactose in milk for lactose intolerant people or prevent lactose 
crystallization particularly at low temperature, β-galactosidase is a 
crucial enzyme in the dairy industry (Gänzle et al., 2008; Nguyen et 
al., 2006; Nguyen et al., 2015; Sani et al., 1999; Splechtna et al., 
2007). In addition to the hydrolysis activity, some of these enzymes 
can be used to produce galactooligosaccharides (GOS), widely 
utilized as a prebiotics product, through the transgalactosylation 
reaction (Nguyen et al., 2012). For these industrial purposes, β-
galactosidases are mainly extracted from microorganisms including 
Bifidobacterium (Hsu et al., 2007; Møller et al., 2001) and especially 
from fungi. The production of β-galactosidase from microbes is a 
preferred choice because of a higher yield and thus the relatively 
inexpensive cost of the enzyme. By extension, in order for β-
galactosidase to be used safely in the food industry, microorganisms 
producing β-galactosidase should be food-grade. From this point 
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of view, bifidobacteria are regarded as a good source of β-
galactosidase because of their GRAS (Generally recognized as safe) 
status (Chanalia et al., 2018). 
Bifidobacteria are representative of probiotics defined as non-
pathogenic microorganisms that provide a health benefit to the host 
(Lewis et al., 2016). Since their first discovery by Tissier, these 
microorganisms have been extensively investigated by some 
scientists. Bifidobacteria are saccharolytic microorganisms, and the 
saccharolytic metabolism of bifidobacteria is associated with 
carbohydrate degrading enzymes, particularly glycosyl hydrolases, 
which enable the use of a variety of glycan substrates available in the 
intestines directly or indirectly (Koropatkin et al., 2012; Milani et al., 
2015; Rivière et al., 2016; Turroni et al., 2018). Among the glycosyl 
hydrolases encoded by bifidobacteria, β-galactosidase enables 
bifidobacteria to utilize (human) milk and milk-based substrates, i.e., 
lactose, human milk oligosaccharide (HMO) and GOS (James et al., 
2016; O'Connell Motherway et al., 2013). The hydrolysis and 
transgalactosylation properties of β-galactosidase for milk-based 
substrates have been studied in several bifidobacteria to date (Møller 




Recently, the β-galactosidase activities of 43 lactic acid bacteria 
were assessed. Among them, Bifidobacterium longum RD47 was 
found to be one of the bifidobacterial strains with the greatest level 
of β-galactosidase activity (Han et al., 2014). The whole genome 
sequence of RD47 was identified, and there were three β-
galactosidase genes (G1, G3 and G4) in it. The properties of 
hydrolysis and transgalactosylation were examined for each gene, 
and it was revealed that G1 showed the greatest contribution to the 
hydrolysis and transgalactosylation activity of RD47. The optimal pH 
and temperature for the hydrolytic activity of G1 is pH 8.5 and 40℃, 
respectively, which are moderate for activity in the human colonic 
environment (Oh et al., 2017). Furthermore, G1 yielded maximum 
production of β-GOS (Oh et al., 2017) and an oligosaccharide with 
a new structure (data not shown) at pH 8.5 and 45℃.    
The aim of this study was to obtain a new recombinant bifidobacteria 
with significant β-galactosidase expression by inserting several 
bifidobacterial promoters upstream of the G1. The recombinant 
bifidobacteria were used to remove lactose in milk in this study and 
will be used in a future study to determine whether the alleviation of 
lactose intolerance depends on the β-galactosidase activity of 
bifidobacteria. Incidentally, the strength and characteristics of 
several bifidobacterial promoters which are known to be 
constitutively strong shown by previous studies were compared. 
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3.2 Materials and Methods 
 
3.2.1 Bacterial strains, plasmid DNA and culture 
conditions 
The bacterial strains and plasmids used in this study are listed in 
Table 3.1. E. coli were grown at 37℃ in Luria-Bertani (LB) medium 
(BD Difco™, Sparks, MD, USA) with shaking at 150 rpm. 
Bifidobacteria were cultured at 37℃ in Man Rogosa Sharpe (MRS) 
medium (BD Difco™) containing 0.05% L-cysteine∙HCl.  
Antibiotics were used at the following concentrations: 100 μg/ml 
ampicillin (BIO BASIC INC., Markham, ON, Canada) for E. coli and 3 









Table 3.1 Bacterial strains and plasmids used in this study 
 
Strains and Plasmids Description Source or reference 
Bacterial strains   
Bifidobacterium bifidum BGN4 
wild type; Transformation host; Original source 
of P919 
Isolated from breast-fed infant 
feces (Park et al., 1999b) 
B. longum RD47 wild type; Original source of G1 
Isolated from breast-fed infant 
feces 
B. pseudocatenulatum SJ32  wild type; Original source of P504 
Isolated from healthy human feces 
(Park et al., 1999c) 
B. lactis SH5 wild type; Original source of P572 Isolated from healthy human feces 
Escherichia coli DH5α 
φ80dlacZΔM15 Δ(lacZY-argF)U169 deoR 
recA1 endA1 hsdR17(rK−mK+) sup E44 thi-1 




BGN4+pBES2 B. bifidum BGN4 harboring pBES2 This work 
BGN4+G1 B. bifidum BGN4 harboring pB-G1 This work 
BGN4+P504G1 B. bifidum BGN4 harboring pB-P504G1 This work 
BGN4+P572G1 B. bifidum BGN4 harboring pB-P572G1 This work 
BGN4+P919G1 B. bifidum BGN4 harboring pB-P919G1 This work 
B. lactis AD011 
B. lactis RD68 
Lactic acid bacteria in nature 
Lab stock 
B. longum RD65  
B. longum RD72  
B. longum BORI  
B. longum RD03  
B. pseudocatenulatum INT57  
Lactobacillus casei KFRI 699  
L. plantarum KFRI 708  
L. sakei KOK  
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B. bifidum KCTC 3418  
Purchased from Korean Collection 
for Type Culture 
B. breve KCTC 3419  
B. bifidum KCTC 3440  
B. pseudocatenulatum G4 KCTC 3223  
B. angulatum KCTC 3236  
B. catenulatum KCTC 3221  
B. infantis KCTC 3249  
B. breve KCTC 3220  
B. bifidum KCTC 3202  
L. delbrueckii bulgaricus KCTC 3635  
L. rhamnosus KCTC 3237  
L. acidophilus KCTC 3168  
Streptococcus thermophilus KCTC 3779  
Streptococcus thermophilus KCTC 5092   
Lactococcus lactis KCTC 2013  
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B. breve ATCC 15700  
Purchased from American Type 
Culture Collection 
B. adolescentis ATCC 15703  
B. animalis ATCC 25527  
Leuconostoc mesenteroides ATCC 27258  
Lactococcus cremoris ATCC 19257  
B. thermophilum KCCM 12097 
 Purchased from Korean Culture 
Center of Microorganisms 
Plasmids   
pBES2 
7.6kbp, ApR, CmR, Bifidobacterium – E. coli 
shuttle vector 
(Park et al., 2003) 
pB-G1 
11kbp, pBES2 derivate, containing PG1-G1 
expression cassette 
This work 
pB-G1ORF 10.7kbp, pBES2 derivate, containing G1ORF This work 
pB-P504G1 


















3.2.2 DNA molecular cloning and transformation 
 The target DNA fragments were amplified using TAKARA 
PrimeSTAR GXL DNA Polymerase (TAKARA, Kusatsu, Japan), and 
each primer set is listed in Table 3.2. First, the DNA fragment 
encoding the β-galactosidase, G1, was PCR-amplified from B. 
longum RD47 and cloned into pBES2 via XbaI and EcoRI to construct 
pB-G1. Second, the DNA fragment encoding the β-galactosidase 
open reading frame (ORF) without the promoter, G1ORF, was PCR-
amplified from RD47 and cloned into pBES2 via KpnI and EcoRI to 
construct pB-G1ORF. To investigate the regulatory effects of the 
bifidobacterial promoter, regions of different gene promoters, P504, 
P572 and P919, were amplified from B. pseudocatenulatum SJ32, B. 
lactis SH5 and B. bifidum BGN4, respectively. The amplified putative 
promoter sequences were cloned into the XbaI and KpnI sites of pB-
G1ORF to incorporate the promoter upstream from the β-
galactosidase.  
Successful cloning was confirmed by nucleotide sequencing. Each 
sub-cloned vector was introduced into E. coli via heat-shock and 
the CaCl2 method and introduced into B. bifidum BGN4 by 
electroporation with the Gene Pulser Xcell Microbial Electroporation 
System (Bio-Rad, Hercules, CA, USA). The positive colonies were 
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A promoter of β-
glucosidase gene in SJ32 






A promoter of β-
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A promoter of ribosomal 
protein gene in BGN4 (Wang 



















3.2.3 DNA manipulation 
The chromosomal DNA of each bacterial strain used in this study 
was isolated with the MGTM Cell Genomic DNA Extraction SV Kit 
(MGmed, Seoul, South Korea). Plasmid DNA was extracted from 
Escherichia coli DH5α transformant harboring pBES2 or each sub-
cloned vector with a Plasmid Purification Mini Kit (Nucleogen, 
Gyeonggi-do, South Korea) and methylated in vitro by GpC (M.CviPI) 
methyltransferase (NEB, Ipswich, MA, USA). To identify the plasmid 
from the B. bifidum BGN4 transformants, plasmid DNA was extracted 
with a Plasmid Purification Mini Kit (Nucleogen) following an initial 
lysis step. Cells were resuspended in lysis buffer supplemented with 
lysozyme (20 mg / ml) and incubated at 37℃ for 1 h. The extracted 
DNA was identified by sequencing and comparing the restriction 
patterns with the original plasmid DNA derived from E. coli. 
 
3.2.4 Enzyme preparation and assay 
The incubated bacteria were centrifuged (10,000 ×g for 3 min at 
4℃), and the harvested pellet was washed with 50 mM sodium 
phosphate buffer (pH 7.0). The washed cells were resuspended in 
the phosphate buffer (pH 7.0) and disrupted with a sonicator (Q500; 
K-corporation, Gyeonggi-do, South Korea) for 1.0 s with 1.0 s off 
intervals for 10 min in E. coli and 15 min in bifidobacteria. The 
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disrupted bacterial solution was centrifuged at 10,000 ×g for 10 min 
at 4℃, and the supernatant was used as a crude enzyme extract to 
assay the β-galactosidase activity.  
The relative enzyme activity was measured by the release of para-
nitrophenol from para-nitrophenyl (ρNP) β-D-galactopyranoside 
(Sigma Aldrich, St. Louis, MO, USA). 80 ㎕ of the crude enzyme 
extract were added to 20 ㎕ of 5 mM ρNP β-D-
galactopyranoside suspended in a 50 mM sodium phosphate buffer 
(pH 7.0). The mixture was incubated at 37℃, and the reaction was 
stopped by adding 100 ㎕ of 1 M Na2CO3. The activity was measured 
in a 96-well microplate at 405 nm with a spectrophotometer (Model 
680 Microplate reader; Bio-Rad, Hercules, CA, USA). One unit (U) 
of enzyme activity was defined as the amount of enzyme that 
liberated 1 µmol of ρNP per minute at 37℃ and pH 7.0. The 
volumetric activity (enzyme activity level relative to ml fermentation 
broth) was determined as units of β-galactosidase activity. The 
protein concentration was calculated according to the Bradford 
method (Bradford, 1976).  
 
3.2.5 Investigation on the effects of various carbon 
sources on β-galactosidase expression  
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To investigate the effects of various carbon sources on the 
expression of β-galactosidases, glucose, fructose, galactose, 
arabinose, cellobiose, maltose, sucrose, raffinose (all from Sigma 
Aldrich, St. Louis, MO, USA) or lactose (Trade TCI Mark, Tokyo, 
Japan) at a 2% concentration was added into the MRS medium or 
MRS medium without glucose. Transformants and non-
transformants were inoculated with these modified MRS media and 
incubated for 18 h at 37℃. β-galactosidase activities were assayed 
as described above. 
 
3.2.6 Plasmid stability test 
The stability of the plasmids constructed in this study was tested 
under non-selective conditions. Approximately 102 bacteria were 
inoculated in 8 ml of MRS and grown for 24 h. In these growth 
conditions, the number of bacteria in the culture reached 
approximately 5.0 x 108 to 2.0 x 109 CFU / ml, which corresponds to 
approximately 20 generations. The culture was diluted and inoculated 
in a new medium and cultured under the same conditions. After 100 
generations, the plasmid stability was assessed by plating diluted 
aliquots on MRS agar medium with or without chloramphenicol and 




3.2.7 Hydrolysis of milk lactose by enzyme or 
transformants 
Commercial milk from Seoul milk (Seoul dairy cooperative, Seoul, 
South Korea) was heated to 95℃ for 30 minutes for further 
sterilization and elimination of dissolved oxygen.  
Then, 50 ㎍ of the crude enzyme extract produced by the method 
described above were added to 1 ml of the prepared milk. The 
mixtures were incubated for 8 h at 40℃, which is the optimal 
temperature for the hydrolytic activity of G1. After the incubation, 
each mixture was boiled at 100℃ for 5 min in order to inactivate the 
enzyme, and samples for HPLC were prepared as described by 
Marsili et al. (Marsili et al., 1981). Thus, 1 ml of water and 4 ml of 
acetonitrile were added to each 1 ml of sample and them shaken for 
1 min and centrifuged to obtain a clear supernatant. The supernatant 
was filtered with a 0.2 ㎛, 13 mm PVDF Acrodisc syringe filter (Pall 
Corporation, Michigan, USA). Then, 5 ㎕ were injected for HPLC 
analysis. 
5.0 x 108 CFU of RD47, BGN4, BGN4+pBES2 or BGN4+G1 were 
inoculated into 5 ml of the prepared milk. Incubation was carried out 
at 37℃, the optimum temperature for the bacterial growth, for 93 h. 
After the incubation, each mixture was boiled at 100℃ for 5 min in 
order to inactivate the bacteria, and samples for HPLC were prepared 
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as described above. 
 
3.2.8 HPLC 
The concentration of the lactose was determined by HPLC. The 
YL9100 HPLC system (Younglin, Gyeonggi-do, South Korea) was 
used, which was equipped with a YL9101 vacuum degasser, a 
YL9110 quaternary pump, a YL9131 column department, a 9170 RI 
detector, and a 9150 Autosampler.  
  An YMC-Pack Polyamine Ⅱ, 250 x 4.6 mm column (YMC, 
Gyeonggi-do, South Korea) was used with 75% acetonitrile as 
mobile phase at a flow rate of 1 ml / min. The column temperature 
was constant at 26℃. Calibration was carried out with external 
standards calculated by sugar solutions, for which the concentration 
is known. Samples were analyzed in a triplicate manner. 
 
3.2.9 Statistical analysis of data  
The results generated from this study were subjected to one-way 
analysis of variance (ANOVA) test at a 5% level of significance and 




3.3 Results  
 
3.3.1 Gene cloning and heterologous expression of β-
galactosidase from B. longum RD47 
 To obtain β-galactosidase over-expressing bifidobacteria using a 
heterologous gene from closely related organisms, it was necessary 
to find a gene exhibiting a strong β-galactosidase activity derived 
from bifidobacteria. In the preliminary studies, Bifidobacterium 
longum RD47 was one of the bifidobacterial strains with the greatest 
level of β-galactosidase activity (Han et al., 2014), and it was found 
that there were three β-galactosidase genes (G1, G3 and G4) in the 
full genome of RD47, which were cloned and characterized for 
hydrolysis and transgalactosylation, respectively. Among them, G1 
showed the highest hydrolysis and transgalactosylation activity, and 
I chose it as the gene to be used in my experiment. The size of this 
gene is 3,072 bp, corresponding to 1,024 amino acids and a molecular 
mass of 112.64 kDa. The optimal pH and temperature for the 
hydrolytic activity of G1 are pH 8.5 and 40℃, respectively (Oh et al., 
2017). B. bifidum BGN4 was the transformation host in which G1 was 
expressed heterologously. BGN4, which originated from the feces of 
a breast-fed infant, has been used as a probiotic strain in global food 
markets because of its various benefits. BGN4 exhibits a remarkable 
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colon cell binding ability (Kim et al., 2003; Ku et al., 2009), improves 
the immune function (Hong et al., 2009; Kim and Ji, 2006; Kim et al., 
2007; Lee et al., 2002; Lee et al., 2006) and has anti-tumor effects 
(You et al., 2004). In addition to these features, BGN4 is a relatively 
genetically accessible strain among bifidobacteria and is therefore 
suitable for use as genetically engineered probiotics (Park et al., 
2018).  
 G1 was amplified from the genome of RD47 and subcloned into 
pBES2 with combinations of several bifidobacterial promoters 
including its own promoter and transformed into BGN4 as the host. 
Information about the bifidobacterial promoters used in this study is 
listed in Table 3.2.  
 
3.3.2 Comparison of hydrolytic activities between 
transformants and non-transformants 
Strong promoters are required to promote the expression of a 
target gene. In previous studies, the strengths of various 
bifidobacterial promoters were compared using glucosidase as a 
reporter gene in BGN4. Among them, P504, P572 and P919 were 
relatively strong and constitutive (Wang et al., 2012; Youn et al., 
2012). P504, P572 and P919 originated from B. pseudocatenulatum 
SJ32, Bifidobacterium animalis subsp. lactis SH5 and B. bifidum 
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BGN4, respectively. To develop bifidobacteria that strongly express 
β-galactosidase, I decided to use these promoters. G1 was 
expressed in BGN4 with combinations of P504, P572, P919 or its 
own promoter. The β-galactosidase activities of the recombinant 
bifidobacteria were determined using ρNPG as the substrate to 
compare the strengths of the promoters. As a result, BGN4+G1, 
which is BGN4 in which G1 is expressed with the combination of its 
own promoter, exhibited the highest hydrolytic activity (Fig. 3.1). 
When the enzymatic activities of the cultures incubated for 18 h were 
compared, the β-galactosidase activity of BGN4+G1 was 
approximately 4 times higher than that of wild-type BGN4 and 6 
times higher than that of wild-type RD47, the original host of G1 (Fig. 
3.1.A). The strength of the promoters was in the order of the G1 
promoter followed by P572, P919 and P504 at 18 h incubation. 
However, when the incubation time was varied from 12 h to 30 h, the 
order of the other promoter strengths, except for the G1 promoter, 
was different according to the incubation time (Fig. 3.1.B). BGN4+G1 
exhibited the highest hydrolytic activity regardless of the incubation 
time, for which the enzyme activity was 2.5 to 4.2 times higher than 
that of BGN4. Many previous studies reported that the consensus 
sequences (−35 and −10 regions) (Li and Zhang, 2014; McCracken 
et al., 2000), spacer sequences (Jensen and Hammer, 1998; Li and 
Zhang, 2014), TG motif (Helmann, 1995), UP elements (Estrem et 
al., 1998) and the promoter’s structural properties (Kumar and 
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Bansal, 2018) affect the promoter strength. The promoters used in 
this study seem to differ in strength due to differences in those 
factors.  
I next compared the enzymatic activities of the recombinants with 
35 wild-type lactic acid bacteria present in nature including 
Bifidobacterium, Lactobacillus, Streptococcus, Leuconostoc and 
Lactococcus (Fig. 3.2). Enzyme activities of the recombinants were 
markedly superior to that of any other lactic acid bacteria used in this 
study. Incidentally, as already known, Bifidobacterium overall had a 
higher β-galactosidase activity than any other genera of lactic acid 
bacteria.  
In a previous study, G1 was ligated into the pColdI Vector system 
(TAKARA) and expressed in E. coli BL21 (Oh et al., 2017). When 
the OD600 of the recombinant E. coli reached 0.4 to 0.6, the 
expression of the cloned gene was induced by adding 1 mM isopropyl 
1-thio-β-D-galactopyranoside (Tokyo Chemical Industry Co., 
Ltd., Japan). The recombinant E. coli was then cultured aerobically 
at 37℃ for 21 h, and the enzyme activity of G1 was the highest at 
this point. At the time when the enzyme activity was the highest, the 
volumetric activity of the G1 recombinant E. coli was 0.46 U/ml 
fermentation broth and that of the BGN4+G1 was 0.85 U/ml 
fermentation broth, for which the G1 expression level of the 
recombinant bifidobacteria was approximately 2 times higher than 
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that of the recombinant E. coli. The utilization of BGN4+G1 is 
expected to be high because BGN4+G1 exhibited a better enzymatic 
activity than any other lactic acid bacteria and the G1 recombinant E. 




























































































Cultivation time  
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Fig. 3.1 Comparison of the β-galactosidase activities between the 
wild-type Bifidobacterium sp. and recombinant BGN4 with various 
vector constructs 
The bacteria were cultured at 37℃ for 12 to 30 h. (A) shows the 
relative activities at 18 h, and (B) shows the volumetric activities at 
incubation times from 12 to 30 h. The β-galactosidase activity was 
determined at 37℃ in 50 mM phosphate buffer (pH 7.0) with ρNPG 
as the substrate. RD47, B. longum RD47; BGN4, B. bifidum BGN4; 
































Fig. 3.2 Comparison of the β-galactosidase activities between 35 
lactic acid bacterial strains and the recombinant BGN4 
The bacteria were cultured at 37℃ for 18 h. The β-galactosidase 
activity was determined at 37℃ in 50 mM phosphate buffer (pH 7.0) 

















3.3.3 Effects of carbon sources on β-galactosidase 
expression 
  The effects of various carbon sources, including glucose, arabinose, 
galactose, fructose, sucrose, lactose, maltose, cellobiose and 
raffinose, on the activities of β-galactosidase from G1 
transformants are shown in Fig. 3.3.  
Among all the glucose-free MRS media with various carbon 
sources added, β-galactosidase in transformants grown on lactose 
had the highest activity at 18 h of cultivation at 37℃ (Fig. 3.3). This 
result was compatible with the results of Hsu CA et al. (Hsu et al., 
2006; Hsu et al., 2005), who reported that lactose is an efficient 
inducer for the synthesis of β-galactosidase. The complete genome 
sequence of BGN4, which is the transformation host used in this 
study, has been determined (Accession No. NC_017999.1). 
According to the annotated gene information in this whole genome 
sequence, the lac operon exists in BGN4, and it suggests that the 
expression of β-galactosidases in BGN4 increases when lactose is 
the only sugar source (Bidart et al., 2018). This might be one of the 
most common causes for the highest β-galactosidase activity of the 
transformants when lactose is used as a carbon source except for 
glucose. At this point, it was wondered if the increased β-
galactosidase activity of the BGN4 transformants in the presence of 
lactose is completely due to the lac operon in the BGN4 and not G1. 
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When the β-galactosidase activity of the wild-type BGN4 is 
subtracted from that of the G1 transformants, the enzyme activity of 
G1 alone can be obtained. The enzyme activity of G1 under lactose 
was at least 3 times more induced compared with the enzyme activity 
of G1 under other sugars used in this study except for glucose (data 
not shown). It means that not only the β-galactosidases of the 
BGN4 itself but also the heterologously expressed G1 was induced 
by lactose. Notably, BGN4+G1 and BGN4+P919G1 only exhibited 
such a phenomenon while the other transformants did not. Because 
the only difference between the former and latter is the promoter 
located upstream of G1, it seems that G1 itself does not react to 
lactose but rather that the promoter is responding. Because G1 is a 
β-galactosidase gene, it is reasonable that the G1 promoter is 
induced by lactose. However, P919 is a promoter for the ribosomal 
protein gene (Wang et al., 2012), and it is not understood why it 
reacts to lactose; thus, further study is needed. Among all the 
promoters used in the experiment, the G1 promoter was the most 
strongly induced under lactose based on the enzyme activity of G1. 
In general, when the various carbon sources were added to the 
MRS medium containing glucose, the β-galactosidase activity 
tended to be greatly higher than that when the various carbon sources 
were added to the MRS medium without glucose. (Fig. 3.3) The case 
of BGN4+G1 under lactose was exceptional because the G1 promoter 
reacted strongly to lactose (Fig. 3.3.A). However, when 2% glucose 
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was added to the MRS medium containing glucose to yield a total of 
4% glucose, the enzyme activity was lower than that when 2% 
glucose was added to the glucose-free MRS, which was consistent 
with previous studies showing that glucose at a high concentration 
inhibited β-galactosidase expression (Bidart et al., 2018; Chan et 
al., 2002; Han et al., 2014; Ilyés et al., 2004; Inchaurrondo et al., 
1998). This phenomenon is known as carbon catabolite repression. 
In bacteria, the phosphotransferase system (PTS) (Bidart et al., 
2018; Chan et al., 2002; Ullmann, 1996) and catabolite 
repressor/activator (Cra) model (Saier Jr and Ramseier, 1996) have 
been identified as mechanisms of carbon catabolite repression. 
Glucose is transported into the cell by PTS, which controls the 
cytoplasmic cAMP concentrations. Because cAMP-CAP complexes 
are required for the transcription of necessary promoters, cAMP 
control by the activities of PTS regulates the expression of genes 
related to the utilization of alternative carbon sources (Chan et al., 
2002). On the other side, the Cra protein, either a repressor or 
activator of gene transcription by interacting with the RNA 
polymerase binding site, binds to the catabolites of glycolytic 
substrates, and these complexes are unable to bind to the DNA 
associated with the RNA polymerase binding site resulting in the 
catabolite repression effect (Saier Jr and Ramseier, 1996). A high 
glucose concentration seems to lower the activity of β-
galactosidase by these mechanisms. 
90 
 
In all the transformants except for BGN4+P572G1, when 2% 
maltose was added to the MRS medium with glucose, the biosynthesis 
of β-galactosidase was highly induced compared to when glucose 
alone was used as a carbon source. On the other hand, 
BGN4+P572G1 had the highest enzymatic activity under the addition 
of 2% sucrose. These results were in contradiction to the results that 
when maltose or sucrose was used as the only carbon source, β-
galactosidase was not induced much (Fig. 3.3). Presumably, sucrose 


























































MRS (w/o glucose) 
   





























































MRS (w/o glucose) 
   





























































MRS (w/o glucose) 
   
    BGN4+P572G1           




























































MRS (w/o glucose) 
   
    BGN4+P919G1           

















Fig. 3.3 Effects of the carbon sources on the production of β-
galactosidase in the recombinant BGN4 
The bacteria were cultured at 37℃ for 18 h, and the β-
galactosidase activity was determined at 37℃ in 50 mM phosphate 
buffer (pH 7.0) with ρNPG as the substrate. ANOVA analysis was 
done independently for the results from the MRS and the results from 
the MRS without glucose. For the results from the MRS, statistically 
significant differences by Duncan’s multiple range test (p < 0.05) 
were indicated by upper case alphabets, and for the results from the 













3.3.4 Effects of non-selective conditions on β-
galactosidase expression 
The experiments from here on were conducted for BGN4+G1 
because it exhibited the greatest β-galactosidase activity among all 
the G1 recombinants. The β-galactosidase expression of the G1 
recombinant under non-selective conditions was next investigated. 
The BGN4+G1 recombinant was inoculated with MRS medium in the 
absence of antibiotics and incubated up to 60 h at 37℃. Up until the 
incubation time reached 60 h, the β-galactosidase activity of 
BGN4+G1 did not decrease in the absence of selection pressure; 
however, at most points, it was rather slightly higher than when 




























Fig. 3.4 Effects of non-selective conditions on β-galactosidase 
expression from the recombinant bifidobacteria 
BGN4+G1 was cultured at 37℃ up to 60 h in MRS medium with or 
without chloramphenicol. The β-galactosidase activity was 
determined at 37℃ in 50 mM phosphate buffer (pH 7.0) with ρNPG 








3.3.5 Plasmid stability under non-selective conditions 
In order to estimate the stability of pB-G1, a pBES2 derivate 
containing the PG1-G1 expression cassette in BGN4, the strain was 
grown in MRS broth without antibiotics. After 100 generations,  
culture aliquots were plated on MRS agar with or without antibiotics 
(Gory et al., 2001). The presence of pB-G1 in the BGN4 colonies 
under the non-selective conditions was identified by comparing the 
restriction patterns with the original plasmid DNA. As a result, the 
number of transformants under nonselective conditions was 
maintained at 100% until 60 generations and thereafter, rapidly 
decreased and finally decreased by 53% after 100 generations 
compared with the selective condition. However, it was maintained 
consistently above a high bacterial count of 5.0 x 108 CFU/ml for the 
entire 100 generations. 
For engineered bacteria, heterologous expression adds an 
unnatural load, which can challenge host cells with a significant 
burden (Ceroni et al., 2015; Ceroni et al., 2018; Silva et al., 2012). 
This metabolic burden can result in a decline of the biomass yield, 
cellular viability, recombinant protein productivity and plasmid 
stability (Carneiro et al., 2013). As bacterial generations proceed, 
the segregational instability of the plasmid appears to have a greater 
impact on the process productivity than on the structural stability, 
especially at higher frequencies under non-selective conditions, 
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and the formation and accumulation of a plasmid-free population 
reduces the final plasmid DNA yields (Oliveira et al., 2009). 
According to the results in this study, in the absence of antibiotics, 
the stability of pB-G1 was maintained at 100% until 60 generations, 
the bacterial counts for the BGN4+G1 transformant were kept above 
5.0 x 108 CFU / ml for 100 generations, and the enzyme activity did 
not decrease for 60 h compared with the selective conditions. It is 
believed that the stability of the subcloned plasmid DNA and the 
recombinant protein expression will promote the use of the 
BGN4+G1 transformant and pB-G1 plasmid in industry or further 
laboratory studies. 
 
3.3.6 Lactose hydrolysis 
Lactose hydrolysis experiments were carried out with BGN4+G1, 
which has the highest enzyme activity among the recombinant 
bifidobacteria, BGN4, BGN4 containing pBES2 (BGN4+pBES2), 
which is the Bifidobacterium-E. coli shuttle vector used for the G1 
subcloning, and RD47 by reacting them with milk and by reacting their 
crude enzyme extracts with milk. The lactose hydrolysis capacity in 




After inoculating 5.0 x 108 CFU of each bacteria into 5 ml of milk, 
the amount of residual lactose in the milk was measured for 0 - 93 
h, and the result is shown in Fig. 5A. BGN4+G1 consumed the most 
lactose in the milk within the same time period, followed by BGN4 
and RD47. This is consistent with the order of β-galactosidase 
activity in each bacteria (Fig. 1). It was reported that only about 30% 
of the lactose is removed from fermented milk products (Harju et al., 
2012), and in reality, BGN4 and RD47 eliminated only 17% and 35% 
of the lactose in the milk at 93 h, respectively. However, BGN4+G1 
removed 50% of the lactose in the milk already at 63 h and finally 61% 
at 93 h. This is about twice the lactose removal rate of conventional 
fermented milk products. 
After inoculating 50㎍ of protein as a crude enzyme extract from 
each bacteria into 1 ml of milk, the amount of residual lactose in the 
milk was measured up to 8 h, and the result is presented in Fig. 5B. 
The β-galactosidase of BGN4+G1 consumed the most lactose in 
the milk within the same time period followed by that of RD47 and 
BGN4. This order is consistent with the order for the volumetric 
activity in the crude enzyme extract of each bacteria. The volumetric 
activities of β-galactosidase in 50 ㎍ of protein for RD47, BGN4, 
BGN4+pBES2 and BGN4+G1 were 0.087, 0.053, 0.041 and 0.166 
U/ml, respectively. The β-galactosidase of BGN4+G1 hydrolyzed 
51% of the lactose in the milk at 2 h, but after that, the enzyme 
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activity sharply decreased, and the lactose in the milk was slowly 


























































































Fig. 3.5 Lactose hydrolysis in milk by bacteria or β-galactosidase 
After reacting the milk and bacteria at 37℃ (A) or the milk and β-
galactosidase of the crude enzyme extract at 40℃ (B) for a certain 
period of time, residual lactose was measured by HPLC. RD47, B. 
longum RD47; BGN4, B. bifidum BGN4; others, B. bifidum BGN4 















 In this study, a β-galactosidase over-expressing bifidobacteria 
strain was developed by using a heterologous gene from B. longum 
RD47 which is one of the bifidobacterial strains with the greatest 
level of β-galactosidase activity. Among the recombinant 
bifidobacteria, BGN4+G1 has the highest β-galactosidase activity, 
for which the hydrolytic activity was 2.5 to 4.2 times higher than that 
of BGN4 and 4.3 to 9.6 times higher than that of the wild-type RD47 
(Fig. 1B). The β-galactosidase level of BGN4+G1 was remarkably 
superior to that of any of the other 35 lactic acid bacteria used in this 
study (Fig. 2). Furthermore, at the time when the enzyme activity 
was the highest, the volumetric activity of BGN4+G1 was 0.85 U/ml 
fermentation broth, which was twice as high as that of the G1 
recombinant E. coli using an overexpression vector. In this regard, 
industrial or research utilization of BGN4 + G1 is expected to be high. 
It has been generally reported that only about 30% of the lactose is 
removed from conventional fermented milk products (Harju et al., 
2012; Ohlsson et al., 2017), and in agreement with this, BGN4, which 
has the second highest β-galactosidase activity among the 35 lactic 
acid bacteria present in nature, only eliminated 35% of lactose in milk. 
Because lactose intolerant subjects will have a problem with these 
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products, when making fermented milk, fermentation by a starter and 
the reaction with β-galactosidase sometimes proceed together 
(Dekker et al., 2019). However, BGN4+G1 solely hydrolyzed 50% of 
the lactose in milk at 63 h and finally 61% at 93 h during fermentation 
(Fig. 5A). This suggests that it is necessary to improve the β-
galactosidase activity of the starter strains by expressing an 
exogenous enzyme or by mutation in order to reduce the residual 
lactose content of fermented milk for lactose intolerant subjects. 
From my results, the G1 expression cassette used to construct 
BGN4+G1 can be used to increase the β-galactosidase activity of 
starter strains using a food-grade vector or CRISPR technology 
because of the safety of the genetic origin and the strong intensity of 
the gene expression. 
Currently, in the production of lactose-free milk, β-galactosidase 
is mainly used, and the process is carried out only in such a way that 
a soluble enzyme is added without using the enzyme-immobilization 
method due to problems with the microbial stability of the final 
product (Dekker et al., 2019). Although BGN4+G1 does not have a 
higher enzyme activity than other recombinant strains (Becerra et al., 
2001; Ding et al., 2018; Yuan et al., 2008), it has an advantage in that 
it is safe because the bacterial host and gene are derived from 
bifidobacteria, the GRAS bacteria, and the β-galactosidase activity 
is remarkably high compared with lactic acid bacteria in nature. 
Furthermore, the β-galactosidase of BGN4+G1 hydrolyzed half of 
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the lactose in whole milk in 2 h using a crude enzyme extract with 50 
㎍ of protein (Fig. 5B), and it is expected to have a greater effect if 
the amount of crude enzyme extract to be used for the reaction is 
increased. The simple purification of β-galactosidase from BGN4-
G1 by using a his-tag will have industrial significance, such as using 



















Lactose intolerance alleviation in  
post-weaning Balb/c mice by feeding  
β-galactosidase high expressing 








4.1 Introduction  
 
 Lactose intolerance (LI) is a condition which features the inability 
to digest lactose due to a deficiency of β-galactosidase (lactase) in 
the digestive tract (Li et al., 2012; Oak and Jha, 2018). Lactase 
deficiency causes lactose to pass into the colon because it is not 
digested and absorbed in the small intestine. Then, lactose is 
converted into short chain fatty acids and gas (methane, hydrogen 
and carbon dioxide) by colonic microflora (Vonk et al., 2012), and 
elevated osmotic pressure caused by the lactose itself and the lactose 
fermentation products increase the intestinal water content. These 
phenomena lead to typical clinical symptoms including diarrhea, 
bloating, abdominal pain, nausea, bloating, flatulence, blanching and 
cramps between 30 min and 2 h after lactose intake (Harrington and 
Mayberry, 2008; Nivetha and Mohanasrinivasan, 2017). Lactose 
intolerant people have poor quality of life activities because of the 
acute clinical symptoms after the intake of lactose-containing foods 
such as milk and milk products (He and Yang, 1999). About 75% of 
the world’s adult population undergo LI, and the prevalence of LI 
varies by race. It has been reported that 5 – 15% of Europeans and 
North Americans, 50 – 80% of Hispanic people, 60 – 80% of 
African-Americans and Ashkenazi Jewish people and almost 100% 
of Asian and American Indian people have a lactase deficiency 
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(Heyman, 2006; Misselwitz et al., 2013). Therefore, LI is a 
worldwide issue in terms of public health management, especially in 
some regions including Asia (Li et al., 2012). 
A common treatment for managing LI tends to exclude milk from the 
diet. However, this approach may have serious nutritional 
disadvantages mainly reducing the intake of calcium, phosphorus and 
vitamins (Montalto et al., 2006). These nutritional limits can lead to 
a lower bone density (Di Stefano et al., 2002) and a significant risk 
of osteoporosis (Savaiano, 2011). Fermented milk is usually thought 
to be an ideal milk substitute for LI subjects, but it was reported that 
only about 30% of the lactose is removed from fermented milk 
products (Harju et al., 2012). To overcome the limits of dietary 
approaches, several studies have been conducted to find alternative 
strategies, such as using exogenous β-galactosidase, yogurt and 
probiotics for their bacterial β-galactosidase activity (Montalto et 
al., 2006). Among them, probiotics, particularly strains belonging to 
Bifidobacterium and Lactobacillus, have recently attracted attention 
as a potential treatment for lactase deficiency (Oak and Jha, 2018). 
However, contradictory results have been reported in previous 
studies in which probiotics were effective for LI (Almeida et al., 2012; 
He et al., 2008; Hiele et al., 1988; Rabot et al., 2010) or not (Kim 
and Gilliland, 1983; Levri et al., 2005; Park et al., 1999a; Saltzman et 
al., 1999). Concerning this phenomena, Kara M. Levri et al. (Levri et 
al., 2005) suggested that specific probiotic strains seem to be 
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effective for LI, so further studies on specific strains are necessary 
to reveal this potential therapeutic relationship.  
 Recently, a mouse experiment was performed to investigate the 
alleviation of LI by Lactococcus lactis expressing heterologous β-
galactosidase (Li et al., 2012). This study reported that the strain 
used showed the effect of alleviating LI symptoms, and the probable 
mechanism for it was the predominant colonization of lactic acid 
bacteria, mainly Bifidobacterium. I hypothesized that Bifidobacterium 
may be effective in alleviating LI, but the reason for the contradictory 
results of previous studies is that there is a difference in the β-
galactosidase activity between Bifidobacterium strains used in the 
experiments. To prove the hypothesis, the aim of this study was to 
verify the effect of the β-galactosidase activity of bifidobacteria on 
LI alleviation by administering β-galactosidase reduced 
bifidobacteria, wild-type bifidobacteria and β-galactosidase over-
expressing bifidobacteria to post-weaning Balb/c mice which have 








4.2 Materials and Methods 
 
4.2.1 Randomized mutagenesis by MNNG 
Randomized mutagenesis by MNNG (1-methyl-3-nitro-1-
nitrosoguanidine), a chemical mutagen, was performed as described 
by S. A. Ibrahim et al. (Ibrahim and O'Sullivan, 2000) with several 
modifications. Overnight cultures of B. bifidum BGN4 were diluted 
into 8 ml of fresh MRS broth supplemented with 0.05% L-
cysteine∙HCl and incubated until the OD600 reached 0.4 (early-
exponential phase). After centrifugation, the pellet was washed in 1 
ml of 100 mM citrate buffer (pH 5.5). The suspended cells were 
mixed with 1 ml of the same buffer as above containing 5 mg/ml of 
MNNG and incubated at 25℃ with gentle agitation. After 30 min of 
incubation with a mutagen, the mixture was centrifuged and washed 
twice with 1 ml of 100 mM phosphate buffer (pH 7.0). The 
mutagenized cultures were then plated on X-gal based MRS medium. 
All plates were incubated at 37℃ for at least 72 h. Colonies that 
exhibited a relatively white color were selected to assay 
quantitatively the β-galactosidase activities using para-





4.2.2 Assay for β-galactosidase activity 
The β-galactosidase activity was measured by the release of 
para-nitrophenol from para-nitrophenyl (pNP) β-D-
galactopyranoside (Sigma Aldrich, St. Louis, MO, USA). To perform 
this assay, first, a crude enzyme extract of bacteria was prepared as 
follows. The incubated bacteria were centrifuged (10,000 ×g for 3 
min at 4℃), and the harvested pellet was washed with 50 mM sodium 
phosphate buffer (pH 7.0). The washed bifidobacterial cells were 
resuspended in the same buffer and disrupted with a sonicator (Q500; 
K-corporation, Gyeonggi-do, South Korea) for 1.0 s with 1.0 s off 
intervals for 15 min. The disrupted bacterial solution was centrifuged 
at 10,000 ×g for 10 min at 4℃, and the supernatant was used as 
crude enzyme extract to assay the β-galactosidase activity. Thus, 
80 ㎕ of the crude enzyme extract were added to 20 ㎕ of 5 mM 
pNP β-D-galactopyranoside suspended in 50 mM of a sodium 
phosphate buffer (pH 7.0). The mixture was incubated at 37℃, and 
the reaction was stopped by adding 100 ㎕ of 1 M Na2CO3. The 
activity was measured in a 96-well microplate at 405 nm using a 
spectrophotometer (Model 680 Microplate reader; Bio-Rad, 
Hercules, CA, USA). One unit (U) of enzyme activity was defined as 
the amount of enzyme that liberated 1 µmol of pNP per minute at 37℃ 
and pH 7.0. The volumetric activity (enzyme units per ml of 




4.2.3 Bacterial binding to the Caco-2 cell line 
The colonocyte-like cell line Caco-2 was used to investigate the 
adhesion ability of the wild-type BGN4 and mutant BGN4 to the 
mucosal surfaces in the intestine. Caco-2 cells were purchased from 
the Korean Cell Line Bank (KCLB, Seoul, South Korea). The culture 
and maintenance of the cells were carried out following standard 
procedures (Sánchez et al., 2010) using DMEM medium (Gibco 
Invitrogen, Paisley, UK) containing 10% (v/v) fetal bovine serum 
(FBS) and 1% (v/v) antibiotic antimycotic solution. 
For the adhesion assays, cells were seeded at a concentration of 5.0 
X 103 cells/well in 24-well plates until a confluent differentiated state 
was reached, that is, after 14 days in culture and complete 
differentiation. The cell culture medium was changed every 2 days 
and replaced with antibiotic-free DMEM medium 24 h before the 
adhesion test. The viable cell number was about 1.08 X 105 cells per 
well. 
Bifidobacteria were incubated for 18 h and washed twice with PBS 
buffer (pH 7.4) and then resuspended in antibiotic-free DMEM 
medium at a concentration of 109 CFU / ml. Caco-2 cellular 
monolayers were also gently washed with PBS buffer (pH 7.4), and 
bacterial suspensions were added to a final count of 109 CFU. 
Adhesion experiments were carried out for 1 h at 37℃ in a 
humidified atmosphere of 5% CO2, and afterwards, the wells were 
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carefully washed to remove any unattached bacteria. After 
detachment with 0.25% Trypsin–EDTA solution (Sigma, St. Louis, 
MO, USA), the cells were transferred to a 1.5 ml tube. The wells 
were rinsed with 200 ㎕ PBS buffer (pH 7.4) which was also 
transferred to the 1.5 ml tube above. The bacteria attached to the 
Caco-2 cells were quantified by real-time PCR. 
 
4.2.4 Experimental animals 
All animal study designs and procedures were approved by the local 
animal ethics committee at the Seoul National University (approval 
number : SNU-180917-1-1). Animals were maintained and treated 
in accordance with the guideline of the Institute of Laboratory Animal 
Resource (Seoul National University, Seoul, South Korea). Post-
weaning Balb/c male mice (9–10 weeks old) were used (DBL, 
Chungcheong-do, South Korea). They were maintained in a 
temperature-controlled environment (22 ± 2℃) at a relative 
humidity of 50 ± 10% and a 12 h light/dark cycle. 
 
4.2.5 Animal groups and oral administration of bacteria 
Balb/c mice were acclimatized for a week and randomly divided into 
seven groups (n=14) based on their body weight. They were fed a 
commercial diet, AIN-93G (DYbiotech, Seoul, South Korea) and tap 
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water ad libitum during the experiment. 
The bacterial intake groups were administered daily with 1 × 109 
CFU of lyophilized B. bifidum BGN4, 1 × 109 CFU of lyophilized B. 
bifidum BGN4-pBES2, 1 × 109 CFU of lyophilized β-
galactosidase over-expressing BGN4 (BGN4-G1) or 1 × 109 CFU 
of lyophilized β-galactosidase reduced BGN4 (BGN4-bgr) in a 
normal saline (NS) suspension with a total volume of 200 ㎕, 
respectively. All bacteria to be consumed by the mice were 
lyophilized from Bifido Inc., Gangwon-do, South Korea. For the 
untreated, lactase-treated and uninduced mice, 200 ㎕ of NS were 
ingested daily. In the case of the lactase-treated group, a commercial 
lactase tablet with an activity of 9,000 U/per one tablet dissolved in 
a NS suspension with a total volume of 200 ㎕ was administered 
shortly before lactose intolerance induction. The commercial lactase 
used in this experiment was Lactaid Fast Act (HP Hood LLC, 
Lynnfield, MA, USA). Because an adult dose of the lactase product is 
one tablet at a time, the dose of lactase for mice was determined as 
4.6 mg/kg of body weight by converting it assuming that the average 
weight of an adult is 60 kg. 
 
4.2.6 Sample collection 
After daily administration for 2 weeks, all mice were fasted for 12 
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h before lactose challenge. The feces of seven mice from each group 
were collected for microbiome analysis and then challenged with 
lactose (25 g per 60 kg of body weight) to investigate intestinal 
motility. The other seven mice of each group were also challenged 
with the same concentration of lactose as above to investigate stool 
frequency and total feces weight within 6 h post-challenge. At this 
point, the fasting plasma glucose level, the baseline, was measured in 
the tail vein blood just before lactose administration and after the 
lactose challenge, and the plasma glucose was again obtained from 
the tail-vein blood 30 min later. After 6 h post-challenge, they were 
sacrificed, and 10 cm of the small intestine near the stomach and 
caecum were anatomized out to measure the intestinal β-
galactosidase activity and SCFA concentrations, respectively.  
 
4.2.7 Diarrhea index determination 
The diarrhea index was measured by the stool frequencies, the total 
feces weight and the intestinal motility. To determine the diarrhea 
index, mice were fasted for 12 h before lactose challenge. The stool 
frequencies and the total feces weight of half of the mice in one group 
were recorded within 6 h post-challenge, and the intestinal motility 
was tested in the other half in one group. For the intestinal motility 
test, mice were orally administered with 0.2 ml of a charcoal 
suspension containing 10% gum Arabic (Sigma Aldrich, St. Louis, MO, 
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USA) and 5% activated charcoal (Samchun, Seoul, South Korea) 20 
min after lactose challenge, and sacrificed 20 min after the 
administration of the charcoal suspension. Then, the small intestine 
was anatomized out from the pylorus to the ileocecal junction, and 
the distance from the pylorus to the front edge of the charcoal 
particle and the total length of intestine anatomized out were 
measured, respectively. The percentage of the running distance of 
the charcoal particle in total small intestinal length was calculated to 
express the intestinal motility. 
 
4.2.8 Measurement of the β-galactosidase activity in 
the small intestine 
The small intestine with ten times the volume of ice-cold 0.9% NS 
were homogenized with Tissue-Tearor (985370; BioSpec Products 
Inc., Bartlesville, OK, USA) for 1 min. Then, the cell and tissue debris 
were spun down at 1,000 ×g for 10 min, and the supernatant was 
collected to measure the β-galactosidase activity. The β-
galactosidase activity of the supernatant was determined by the 
release of para-nitrophenol from para-nitrophenyl (pNP) β-D-
galactopyranoside (Sigma Aldrich, St. Louis, MO, USA) as the 
substrate at 37℃ in phosphate buffer at pH 7.0. One unit (U) of 
enzyme activity was defined as the amount of enzyme that liberated 
116 
 
1 µmol of pNP per minute at the given conditions. 
 
 
4.2.9 SCFA analysis  
 The cecal samples (100 mg) were homogenized in 400 ㎕ of DW. 
Thereafter, these were acidified with 25% metaphosphoric acid 
(Sigma Aldrich, St. Louis, MO, USA) at a 1:5 ratio (1 volume of acid 
for 5 volumes of a sample) for 30 min on ice. Samples were then 
centrifuged at 15,000 x g for 15 min at 4℃, and the supernatant was 
stored at -80℃ until it was analyzed by HPLC. 
 The supernatant was injected into an YL9100 HPLC system 
equipped with an YL9170 RI detector and the Younglin Autochro-
3000 data system software (Younglin, Gyeonggi-do, South Korea). 
SCFAs were separated on an Aminex HPX-87H Ion Exclusion 
column (300 X 7.8 mm, 9 ㎛, Bio-Rad, Hercules, CA, USA) which 
was run isocratic with 5 mM sulfuric acid at a flow rate of 0.6 ml per 
min at a temperature of 35℃. 
 




4.2.10.1 DNA extraction from the sample collection 
 The fecal (180 - 220 mg) samples were collected from the mice of 
each group, stored at -80℃ until the genomic DNA was extracted 
and used for DNA extraction. The microbial genomic DNA in the 
stools was extracted using a QIAamp DNA Stool Mini Kit (QIAGEN, 
Hilden, Germany) following an initial bead-beating step and with 
some modifications to increase the DNA concentration. Fecal samples 
were finely ground after lyophilization and transferred to a 2 ml tube 
containing sterile 0.5 mm zirconia beads (BioSpec Products Inc., 
Bartlesville, OK, USA). Then, 1.4 ml of ASL buffer (QIAGEN) were 
added to each tube, and the samples were homogenized by bead-
beating with a tissue lyser (TissueLyser Ⅱ; QIAGEN) for 30 s at a 
speed of 30 frequency / s. The lysis temperature and time were 
increased to 95℃ and 10 min, respectively. The extracted DNA 
samples were stored at -20℃ until 16S metagenomic sequencing. 
 
4.2.10.2 Library preparation 
 DNA concentration was measured using a Qubit® 3.0 Fluorometer 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) and diluted to 5 
ng / ㎕. The microbial genomic DNA (5 ng / ㎕) was amplified using 
the amplicon primers with overhang adapters attached targeting 
variable V3 and V4 region of the 16S rRNA gene. An Agencourt 
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AMPure XP beads (Beckman Coulter, Brea, CA, USA) were used to 
purify 16S V3 and V4 amplicon away from free primers and primer 
dimer species. 
 The 16S V3 and V4 amplicon was amplified with dual-index primers 
via PCR and purified with Agencourt AMPure XP beads. The index 
PCR amplicon possessed specific barcode sequences to distinguish 
among each other in the pooled library. 
 The concentrated library was measured using a Qubit® 3.0 
Fluorometer (Thermo Fisher Scientific Inc.) and diluted using 
Resuspension Buffer (RSB; Illumina, San Diego, CA, USA) to 4 nM. 
5 ㎕ aliquot of diluted DNA from each samples were mixed for 
pooling libraries. 
 
4.2.10.3 Sequencing via an Illumina MiSeq platform 
 A pooled library was denatured with NaOH, diluted to 8 pM with 
hybridization buffer (HT1; Illumina). A PhiX control library (Illumina) 
was denatured with NaOH, diluted to 8 pM with HT1. The pooled 
library was mixed with the PhiX control (30%, v/v) and the combined 
library and PhiX control was loaded on a MiSeq® v2 (500 cycle) 
Reagent cartridge (Illumina) for sequencing. All sequencing 





4.2.10.4 Sequencing data processing  
Sequencing analysis, including demultiplexing and removal of 
indices, was performed using the bacterial metagenomics workflow 
in the MiSeq Reporter software (Illumina). The classification step 
uses a proprietary algorithm that provides each taxonomic level 
classification for paired-end reads.  
 
4.2.11 Statistical analysis 
In the graphs related to LI symptoms (Fig. 1 – Fig. 5), results were 
compared using an unpaired, one-tailed nonparametric t test using 
GraphPad Prism 8 software to compare each experimental group to 
untreated group. Significant P values for all comparisons are 
depicted in figures as follows: *P < 0.05, **P < 0.01, and 
***P < 0.001. 
 In the graphs related to microbiome and SCFA analysis (Fig. 6 – 
Fig. 9), results were compared using a nonparametric one-way 
ANOVA test (Kruskal-Wallis H) and post-hoc test (Dunn’s 
multiple comparisons test) in GraphPad Prism 8 software. Significant 
P values for all comparisons are depicted in figures as follows: 





4.3.1 Construction of the β-galactosidase reduced 
and over-expressing B. bifidum BGN4 
To investigate the effect of the β-galactosidase activity of 
Bifidobacterium on LI, construction of the β-galactosidase reduced 
and over-expressing bifidobacteria by genetic modification was 
required. The bifidobacterial strain used in this study was selected 
as B. bifidum BGN4 because it is genetically accessible (Park et al., 
2018) and has a remarkable colon cell adhesive ability among the 
other bifidobacteria (Kim et al., 2003; Ku et al., 2009). Previously, I 
constructed a recombinant BGN4 strain expressing heterologous β-
galactosidase, BGN4-G1 (unpublished study). Because the β-
galactosidase activity of BGN4-G1 was 2.5 to 4.2 times higher than 
that of the wild-type BGN4 and markedly superior to those of the 35 
wild-type lactic acid bacteria, BGN4-G1 was chosen as the β-
galactosidase over-expressing strain against the wild-type BGN4 in 
this study. Meanwhile, β-galactosidase reduced BGN4 was obtained 
by randomized mutagenesis of BGN4. Because BGN4 has six putative 
β-galactosidase genes in its whole genome (Accession No. 
NC_017999.1), it is somewhat unreasonable to obtain a β-
galactosidase-deficient BGN4 strain through targeted mutagenesis. 
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Chemical mutagenesis for BGN4 was conducted as a reliable method 
to yield the lowest kill rate with an acceptable frequency of 
mutagenesis. After the mutagen treatment, 11 colonies were obtained, 
and additional validation experiments were performed. After 
investigating their enzymatic activities, growth rate and colon cell 
binding ability, a strain named BGN4-bgr was finally selected, whose 
β-galactosidase activity was significantly lower than that of BGN4 
and its characteristics, which could inadvertently affect the results of 
this study, are similar to BGN4. The results of the comparison of the 
β-galactosidase activity, growth rate and colon cell adhesive ability 
between the wild-type BGN4 and the mutant are shown in Fig. 4.1. 
Based on the MRS medium, the growth curve of BGN4-bgr was 
similar to that of BGN4 in both cases when glucose (Fig. 4.1.A) or 
lactose (Fig. 4.1.B) was used as the sole carbon source. The growth 
rate of BGN4-bgr tended to be slower at the beginning of the 
incubation, rapidly recovered, and the maximum OD600 and the time 
to reach the value were similar in both BGN4 and the mutant. In the 
MRS medium when glucose was the carbon source, the β-
galactosidase level of the BGN4-bgr was 142.8 times lower than that 
of BGN4 at 12 h of incubation, after which the enzyme activity slightly 
recovered but still 3.7 to 9.7 times lower during the incubation time 
(Fig. 4.1.A). When lactose was the carbon source, the β-
galactosidase activity of the BGN4-bgr was 2.7 to 5 times lower than 
that of BGN4 depending on the incubation time (Fig. 4.1.B). Next, the 
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colon cell binding ability of BGN4 and BGN4-bgr was investigated. 
Because adherence on intestinal epithelial cells is an essential 
process for the colonization of microorganisms in the gut (Kadlec and 
Jakubec, 2014; Parvez et al., 2006), if there is a difference in the 
ability to adhere to the intestine between BGN4 and BGN4-bgr, the 
level of colonization in the gut will be different, which can act as a 
bias in this study. As a result, BGN4-bgr had a tendency to exhibit a 
better colon cell binding ability than BGN4, but there was no 
significant difference (Fig. 4.1.C). Whole genome sequencing of 
BGN4-bgr was performed to investigate whether mutations directly 
occurred in the β-galactosidase genes. Then, the genome of 
BGN4-bgr was compared with the putative β-galactosidase genes 
in BGN4 (Table 4.2). As a result, it was found that mutations 
occurred in two out of five genes. Both of them had a point mutation 
in the protein coding region rather than in the promoter region. These 
direct mutations of β-galactosidase genes in BGN4-bgr are 
considered to be a cause of lower β-galactosidase activity of 
BGN4-bgr than BGN4. 
As mentioned above, the β-galactosidase reduced BGN4 was 
developed through randomized mutagenesis, so the mutant has the 
limitation that mutations may have occurred not only in genes 
associated with β-galactosidase expression but also in unexpected 
genes that inadvertently affect the results of my experiments. To 
overcome this limitation, I additionally confirmed several factors that 
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might influence this study, such as growth rates and the ability to 
adhere to the intestine, and finally selected the mutant.  
Finally, when the lyophilized bacterial powder for administration to 
mice was resuspended in phosphate buffer (pH 7.0) to a final 
concentration of 109 CFU / ml and the β-galactosidase activity was 
observed after sonication, the BGN4-G1 showed 3.6-fold higher 
enzyme activity than that of the BGN4, and the BGN4-bgr showed 
3.2-fold lower enzyme activity than that of the BGN4. It is 
considered that the bifidobacterial strains used in the LI alleviation 
experiment were well established according to the degree of β-
galactosidase activity of the bifidobacteria. Bacterial strains used in 


























































































Fig. 4.1 Comparison of the β-galactosidase activity, growth rate and 
colon cell adhesive ability between BGN4 and BGN4-bgr  
BGN4 and BGN4-bgr were cultured up to 36 (B) or 42 h (A) in MRS 
medium in which glucose (A) or lactose (B) was used as a carbon 
source, and their β-galactosidase activity and OD600 for the growth 
rate were measured at incubation times from 12 to 36 (B) or 12 to 
42 h (A). In the (A) and (B), the black bar, closed circle or closed 
triangle represents BGN4-bgr and the white bar, open circle or open 
triangle represents BGN4. The β-galactosidase activity was 
determined at 37℃ in 50 mM phosphate buffer (pH 7.0) with ρNPG 
as a substrate. The colon cell adhesive ability was expressed as the 
number of bacteria attached to one caco-2 cell (C).
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Bacterial strain Description Source or reference 
BGN4-G1 
B. bifidum BGN4 harboring pB-G1 which is a pBES2 derivate 
containing β-galactosidase-expression cassette 
Lab stock 
BGN4 Wild-type B. bifidum BGN4 
Isolated from breast-fed infant feces 
(Park et al., 1999) 
BGN4-pBES2 B. bifidum BGN4 harboring pBES2 Lab stock 
BGN4-bgr 
B. bifidum BGN4 with reduced β-galactosidase activity by 
chemical mutagen. 
This work  
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β-galactosidase gene  




Begin End DNA change 
1 170425 174300 - 
2 190263 192443 - 
3 575594 581401 577838 G→A 
4 1595246 1597315 1595952 C→T 
5 1712272 1715430 - 
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4.3.2 Stool frequency and total feces weight for 6 h 
after lactose administration 
 Seven experimental mice groups were exposed to lactose challenge 
after a daily intake of bacteria or normal saline (NS) for 2 weeks. 
The seven experimental groups were as follows: 1) a group treated 
with wild-type BGN4, 2) a group treated with BGN4 containing 
pBES2 which is the Bifidobacterium-E. coli shuttle vector used for 
G1 subcloning, 3) a group treated with BGN4-bgr (β-galactosidase 
reduced BGN4), 4) a group treated with BGN4-G1 (β-
galactosidase over-expressing BGN4), 5) LI-induced, but untreated 
group, 6) a group treated with lactase just prior to LI challenge, and 
7) LI-uninduced group. The stool frequencies were recorded, and 
the feces were collected and weighed until 6 h after the lactose 
challenge. 
For the stool frequency, the lactase-treated group, BGN4-bgr, 
BGN4, and BGN4-pBES2 administration groups showed a tendency 
to have a decreased number of feces, but it was not a statistically 
significant difference compared with the untreated group (Fig. 4.2.A). 
On the other hand, in the case of the BGN4-G1 group, the number of 
stools was significantly decreased. There was no significant 
difference in the BGN4-G1 group compared to the uninduced group, 
indicating that the LI symptoms were alleviated to a level similar to 
the uninduced group. 
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In all the groups, the total feces weight tended to decrease compared 
to the untreated group, but only the uninduced group, lactase-treated 
group, and BGN4-G1 administration group were statistically 
significant (Fig. 4.2.B). In particular, the BGN4-G1 group had a 
greater difference in significance than that of the lactase-treated 
group and did not differ significantly from the uninduced group, 
indicating that the degree of LI alleviation in the BGN4-G1 group was 







































































































































































Fig. 4.2. Stool frequency and total weight of feces within 6h post-
lactose challenge in mice 
Total number of feces were recorded (A) and weighed (B) for each 








4.3.3 Intestinal motility after lactose challenge 
From the result shown in Fig. 4.3, a significant decrease in the 
running distance of the charcoal particle in both the BGN4 and 
BGN4-G1 groups compared with the untreated group was observed 
although it did not reach the level of the uninduced group. Unlike the 
BGN4 and BGN4-G1 groups, there was no suppression of intestinal 
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Fig. 4.3 Intestinal motility after lactose challenge in mice 
Intestinal motility was expressed as percentage of the running 








4.3.4 Effect on lactose metabolism  
The metabolism of lactose in the small intestine of mice can be 
measured through the blood glucose after an acute lactose challenge 
(During et al., 1998). The difference in blood glucose between the 
baseline and the value after the 30 min post-lactose is shown in Fig. 
4.4. As expected, the blood glucose did not rise in the uninduced 
group but was somewhat lower or similar to the baseline. The other 
mice groups had an overall elevation in the plasma glucose, 
suggesting that the lactose intolerance model mice used in this study 
do metabolize lactose in the small intestine to some extent. The 
change in the plasma glucose level tended to be slightly higher in the 
mice groups fed lactase or bifidobacteria compared to the untreated 
group but was not statistically significant. The lactase-treated group 
was thought to be significantly different from the untreated group 
because the mice were directly administered with a highly active 
lactase just before the lactose challenge, but the result was 
unexpected. Notably, the bifidobacteria, which mainly live in the colon 
rather than in the small intestine, seemed to be slightly involved in 
the lactose metabolism of the small intestine because the blood 
glucose was increased to a level similar to the lactase-treated group 


































































































Fig. 4.4. Change in plasma glucose after the ingestion of lactose in 
mice fasted overnight 
Fasting plasma glucose level, as the baseline, was measured in tail 
vein blood just before lactose administration. After the lactose 
challenge, the plasma glucose was again obtained from the tail-vein 
blood 30 min later. Change in plasma glucose was expressed as the 
difference in blood glucose between the baseline and the value after 




4.3.5 Small intestinal β-galactosidase activities  
In this study, LI symptoms were alleviated with the increasing β-
galactosidase activity of bifidobacteria. To investigate the mechanism 
of the results, the β-galactosidase level in the small intestine of 
mice after 6 h post-lactose was measured. This value may reflect 
the β-galactosidase activities of the small intestine itself and the 
bacteria present in the small intestine such as Lactobacillus, 
Lactococcus, etc. As expected, the lactase fed group showed a 
significantly increased β-galactosidase activity  compared with 
that of the untreated group (Fig. 4.5). The bifidobacteria 
administration groups except for the BGN4-pBES2 group showed a 
slightly higher enzyme activity than that of the untreated group, but 
the difference was not significant. In addition, there was no observed 
tendency in the result based on the β-galactosidase activity of the 
bifidobacteria. Taken together with the results of the plasma glucose 
levels (Fig. 4.4), this may suggest that the mechanism of LI 
alleviation as the increases of β-galactosidase activity from the 
bifidobacteria is not much related to the lactose metabolism in the 
small intestine by the β-galactosidase activities of the small 
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Fig. 4.5. Small intestinal β-galactosidase activity in mice 
After 6 h post-challenge, 10 cm of small intestine near the stomach 
were anatomized out and homogenized with ten times volume of ice-
cold 0.9% NS. Then, the cell and tissue debris were spun down, and 
the supernatant was used to measure the β-galactosidase activity. 
The β-galactosidase activity was determined at 37℃ in 50 mM 





4.3.6 Microbial diversity 
From the above results, it was found that a better lactose tolerance 
by the β-galactosidase-overexpressing bifidobacteria was not 
significantly associated with lactose metabolism in the small intestine. 
Therefore, it was necessary to explore the mechanisms of LI 
alleviation from other aspects. Previous studies have reported that 
LI is also associated with intestinal flora (Deng et al., 2015; Kopp-
Hoolihan, 2001). Based on this viewpoint, a gut microbiome analysis 
from the feces of the mice fed BGN4-bgr, BGN4, BGN4-G1 or NS 
for two weeks was performed to investigate the LI alleviation 
mechanism. 
First, the results for alpha-diversity (within samples) are shown in 
Fig. 4.6. The community richness was assessed by the number of 
observed OTUs (Fig. 4.6.A), Shannon index (Fig. 4.6.B) and Faith's 
phylogenetic diversity (Fig. 4.6.C), and the evenness was presented 
by Pielou’s evenness index (Fig. 4.6.D). In all cases of richness, the 
lowest median value was seen in the untreated group. Especially 
when evaluated by the Shannon diversity index which considers both 
the species richness and evenness (Chen et al., 2016), the groups 
fed Bifidobacterium were tied together, and the untreated group 
showed a tendency of richness lower than that. Moreover, for 
evenness, the median value of the groups fed Bifidobacterium was 




























































































































































Fig. 4.6 Alpha diversity in mice feces 
Bacterial richness index graphs (Number of observed OTUs (A), 
Shannon index (B), and Faith’s phylogenetic diversity (C)) and 
evenness index graph (Pielou’s evenness index (D)) were obtained 

















4.3.7 Bacterial OTU abundances at the phylum 
taxonomic level  
Next, the OTU abundances for each mouse group at the phylum level 
were calculated and presented in Fig. 4.7. The untreated group had a 
lower proportion of Firmicutes and a higher proportion of 
Bacteroidetes than the groups fed Bifidobacterium although not 
statistically significant due to the large differences among the mouse 
individuals (Fig. 4.7.A). In accordance with these results, the ratio 
of Firmicutes / Bacteroidetes tended to be higher in the groups fed 
Bifidobacterium compared with the untreated group (Fig. 4.7.B). 
The phyla Bacteroidetes and Firmicutes are generally dominant in 
the intestine of healthy humans (Johnson et al., 2017). It has been 
reported previously that the abundance of Firmicutes was less and 
that of Bacteroidetes was greater in IBD patients compared to healthy 
subjects (Marteau, 2009; Wright et al., 2015). However, the opposite 
result was also reported by Rooks MG et al. (Rooks et al., 2014). 
These contradictory results may simply be caused by the mouse 
model used. Regardless of the outcomes, the crucial point is that 
Firmicutes and Bacteroidetes contain both colitis- and health-
associated genera (Jones-Hall and Nakatsu, 2016). Meanwhile, a 
previous study showed that sensitivity to lactose occurs in a high 
proportion of IBD (Inflammatory bowel disease) patients (Eadala et 
al., 2011). It is notable that the proportion of the two dominant 
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phylum (Firmicutes and Bacteroidetes) related to colonic health was 
changed from one another according to whether Bifidobacterium or 
NS was ingested, and the Bifidobacterium-intake groups, especially 










































































































Fig. 4.7 The OTU abundances at the phylum level in mice feces 
Overall microbiota composition of the average relative abundance of 
each group at the phyla level (A) and ratio of Firmicutes : 







4.3.8 Bacterial OTU abundances at the genus 
taxonomic level 
Bacterial OTU abundances for each mouse group at the genus 
taxonomic level are shown in Fig. 4.8. There was no significant 
difference, but Bifidobacterium and Lactobacillus were increased in 
the groups fed Bifidobacterium compared to the untreated group (Fig. 
4.8.C, 4.8.D). It is natural that the relative abundances of 
Bifidobacterium were increased in the Bifidobacterium-intake 
groups, but the increase in Lactobacillus was not expected as much. 
This phenomenon might be due to the correlation between 
Bifidobacterium and Lactobacillus (Li et al., 2012). In the case of 
Bifidobacterium, although the mean value of relative abundance in the 
BGN4-G1 group was higher than that of the BGN4 and BGN4-bgr 
groups, there was no significant tendency for the colonization of 
Bifidobacterium according to the β-galactosidase activities 
between the Bifidobacterium-intake groups. The proportion of 
Oscillospira was higher in the groups fed Bifidobacterium, and 
especially in BGN4-G1, Oscillospira was significantly higher 
compared to the untreated group (Fig. 4.8.E). Recently, a meta-
analysis of five microbiota studies in IBD patients reported 
Oscillospira to be significantly reduced in patients with Crohn's 
disease (Walters et al., 2014), which means that Oscillospira is 
positively related to gut health (Konikoff and Gophna, 2016). 
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Meanwhile, the abundance of Bacteroides was not significant but was 
higher in the untreated group than in the groups fed Bifidobacterium, 
which seemed to influence the proportion of Bacteroidetes at the 
phylum level (Fig. 4.8.B). Finally, the ratio of Bifidobacterium to 
Enterobacteriaceae (B/E ratio) was investigated (Fig. 4.8.F). The 
B/E ratio is a typical indicator for the resistance of the 
gastrointestinal tract against the colonization of potentially 
pathogenic microbes (Si et al., 2004; Wu et al., 2000). The untreated 
group had a lower B/E ratio than the groups fed Bifidobacterium, 
















































































































































































































































































































































































Fig. 4.8 The OTU abundances at the genus level in mice feces 
Overall microbiota composition of the average relative abundance of 
each group at the genus level (A) and comparison of relative 





4.3.9 SCFAs and lactate concentration in the cecum 
SCFAs (Short chain fatty acids) and lactate are fermentation 
products of the gut microbiota. Food components that are 
unabsorbed/undigested in the small intestine are fermented in the 
colon to produce SCFAs including acetate, propionate and butyrate 
(Russell et al., 2013). Lactate is also produced by several microbiota 
components such as Bifidobacterium, Lactobacillus and 
Proteobacteria (Flint et al., 2015). SCFAs are associated with a 
reduced risk of several intestinal diseases including irritable bowel 
syndrome and IBD (Hijova and Chmelarova, 2007). 
In this study, the SCFA contents and lactate were incidentally 
measured in the cecum of mice fed BGN4-bgr, BGN4, BGN4-G1 or 
NS for two weeks to analyze the changes in the intestinal metabolites 
by the administered bacteria. Because rats are cecal fermenters, 
unlike humans which are colonic fermenters, many mice and rat 
studies analyze the cecal samples to determine the amount of SCFAs 
(Apajalahti et al., 2002; Campbell et al., 1997; Kleessen et al., 1997). 
As a result, acetate and butyrate showed a tendency to increase in 
the BGN4-G1 and BGN4 groups compared to the untreated group 
although not significant, but the mean value of the BGN4-bgr group 
was similar to that of the untreated group (Fig. 4.9.C, 4.9.D). The 
lactate content of all the Bifidobacterium-fed groups was 
significantly greater than that of the untreated group, and especially, 
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the BGN4-G1 and BGN4 groups had a P value of less than 0.01 (Fig. 
4.9.A). In the case of propionate, the propionate concentration in the 
cecum of the BGN4-G1 and BGN4 groups was significantly higher 
than that of the untreated group, but the BGN4-bgr group did not 
show any significant difference (Fig. 4.9.B). Because Bifidobacterium 
and Lactobacillus are representative producers of lactate and acetate 
(Beards et al., 2010), the increase in lactate and acetate in the 
Bifidobacterium-fed groups may be due to the OTU abundance 
increase of Bifidobacterium and Lactobacillus in these groups, 
although it was not significant (Fig. 4.8). In the intestine, the 
produced lactate and acetate are converted to propionate and 
butyrate through cross-feeding by other dominant members of the 
gut microbiota (Beards et al., 2010). The reason for the increase of 
butyrate and propionate in the Bifidobacterium-fed groups is 
probably because the increased lactate and acetate in these groups 
were actively metabolized by other microorganisms and converted to 
butyrate and propionate. There is a report that SCFAs can contribute 
to the osmotic pressure in the colon (Vonk et al., 2012). In this study, 
although total SCFAs in the Bifidobacterium-intake groups were 
increased compared to the untreated group, LI symptoms were rather 
alleviated in the Bifidobacterium-intake groups. This result may 
indicate that the balanced ratio of the SCFAs is more important than 
the total amount of SCFAs or there are other alleviation factors, 
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Fig. 4.9 Concentration of lactate and SCFAs in 100 mg of mice 
caecum 
The cecal samples (100 mg) were homogenized, acidified with 25% 
metaphosphoric acid and centrifuged. The supernatant was analyzed 

















4.4 Discussion  
 
Probiotics administration has received attention as one of the LI 
treatments. However, because of the contradictory results of 
previous studies, no clear conclusion has been drawn as to whether 
probiotics have an effect on LI. I thought that the conflicting results 
may be due to the different β-galactosidase activities of the 
probiotics strains used in each study and devised experiments using 
bifidobacteria, which have a relatively high β-galactosidase activity 
among the probiotics, with different β-galactosidase levels to 
confirm the hypothesis. Therefore, the present work evaluated in 
vivo the effect of the β-galactosidase activity of bifidobacteria on 
LI alleviation by administering β-galactosidase reduced 
bifidobacteria, wild-type bifidobacteria and β-galactosidase over-
expressing bifidobacteria. 
B. bifidum BGN4 was selected as a wild-type Bifidobacterium strain 
used in this study because of its genetical accessibility and 
outstanding colon cell binding ability among other bifidobacteria. 
Previously, I developed a recombinant BGN4 strain expressing 
exogenous β-galactosidase (BGN4-G1), which shows an average 
of 3.5 times higher enzyme activity than that of the wild-type and 
decided to use it as a β-galactosidase over-expressing BGN4 in 
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the present work. In the case of a β-galactosidase reduced BGN4, 
a strain (BGN4-bgr) showing approximately 3.2 times lower enzyme 
activity than that of the wild-type was developed by randomized 
mutagenesis. Through these processes, the β-galactosidase 
reduced, wild-type, and β-galactosidase over-expressing 
bifidobacteria were prepared for use in this study.  
Balb/c mice known as the LI model mice have been shown to have a 
high lactase activity in the small intestine before weaning and then to 
decrease significantly to a very low level after weaning (9 weeks 
old), as in adult-type hypolactasia in humans (He et al., 2005; Li et 
al., 2012). In this study, the Balb/c mice were grouped and orally 
administered with different live bacterial suspensions or NS for 2 
weeks. After that, the mice were challenged with lactose, and 
symptoms of lactose intolerance were observed. As a result, the 
BGN4-G1 administration group showed a remarkable decrease in 
stool frequency (Fig. 4.2.A) and total feces weight (Fig. 4.2.B) for 6 
h post-challenge and suppression of intestinal motility (Fig. 4.3) 
compared with the untreated group. The LI alleviation effect in the 
BGN4-G1 administration group was greater than that in the lactase-
treated group and even reached a LI-uninduced level. Exogenous 
β-galactosidase has traditionally attracted attention as a strategy to 
manage LI subjects and are currently on the market. To compare 
probiotics with exogenous β-galactosidase for LI alleviation, a 
commercially available lactase tablet was used as a positive control 
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in this study. As mentioned above, the BGN4-G1 intake group 
showed significantly better LI-alleviating effects than that of the 
lactase-treated group, which is meaningful. The orally intake of β-
galactosidase is inconvenient because it must be taken every time 
whenever consuming lactose-containing foods and is not very 
effective due to rapid degradation of the enzyme activity (Zhang et 
al., 2011). In this study, lactose challenge was done 12 h after the 
last administration of Bifidobacterium; however, it was found that the 
LI alleviating effects of the Bifidobacterium highly expressing β-
galactosidase were better than that of the lactase treatment despite 
being administered just before the challenge. Meanwhile, the stool 
frequency and total feces weight of the BGN4 and BGN4-bgr 
administration groups tended to decrease compared to the untreated 
group, but no significant difference was found. In the case of 
intestinal motility, in contrast to the BGN4-bgr group, the BGN4 
administration group was significantly inhibited in intestinal motility 
compared to the untreated group. This suggests that the LI alleviation 
effect is improved as the β-galactosidase activity of the 
bifidobacterial is increased. 
To explore the mechanisms for the demonstrated better lactose 
tolerance of the bifidobacteria highly expressing β-galactosidase, 
the lactose metabolism level in the small intestine was first monitored. 
Because elevated levels of plasma glucose after 30 min post-lactose 
(Fig. 4.4) and β-galactosidase activities of the small intestine (Fig. 
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4.5) in the bifidobacteria-fed groups were not significantly different 
compared to the untreated group, the mechanisms of LI alleviation by 
the β-galactosidase level of bifidobacteria do not seem to have 
much to do with the lactose metabolism in the small intestine by β-
galactosidase activities of the small intestine itself and the bacteria 
present there. 
In previous studies, it has been reported that LI is also associated 
with gut microflora (Deng et al., 2015; Kopp-Hoolihan, 2001). Based 
on this viewpoint, gut microbiome analysis from the feces of mice fed 
BGN4-bgr, BGN4, BGN4-G1 or NS for two weeks was performed 
to investigate the LI alleviation mechanism. As a result, the 
Bifidobacterium-fed groups showed better species richness and 
evenness than that of the untreated group (Fig. 4.6). In the OTU 
abundances at the phylum level, the Bifidobacterium-fed groups had 
a higher proportion of Firmicutes and a lower proportion of 
Bacteroidetes than that of the untreated group although not 
statistically significant (Fig. 4.7). In the OTU abundances at the 
genus level, Bifidobacterium, Lactobacillus, Oscillospira and the B/E 
ratio tended to occupy a higher proportion in the Bifidobacterium-
fed groups compared to the untreated group, and especially in the 
BGN4-G1 group, Oscillospira was significantly higher than in the 
untreated group. Meanwhile, Bacteroides was not significant but was 
lower in the groups fed Bifidobacterium compared to the untreated 
group (Fig. 4.8). The important point of all these gut microbiome 
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results is that the changed factors have all been reported to be 
associated with intestinal health (Jones-Hall and Nakatsu, 2016; 
Konikoff and Gophna, 2016; Si et al., 2004; Walters et al., 2014; Wu 
et al., 2000), and the changes in these factors were clearly 
differentiated according to whether mice were fed Bifidobacterium or 
NS.  
Because SCFAs and lactate are fermentation products of gut 
microbes, the contents of SCFAs and lactate were incidentally 
measured in the cecum of mice fed BGN4-bgr, BGN4, BGN4-G1 or 
NS for two weeks. In all cases, BGN4-G1 and BGN4 had significantly 
higher or a higher tendency compared to the untreated, but BGN4-
bgr did not show a significant difference despite the relative increase, 
or the mean value was similar to the untreated group (Fig. 4.9). 
Although the tendency of the gut microbiome proportion between the 
BGN4 strains with different β-galactosidase levels was not 
revealed conspicuously and significantly, the SCFA and lactate 
contents of the BGN4-G1 and BGN4 administration group, which had 
effects on LI alleviation, tended to be different from the BGN4-bgr 
group. 
The gut microbiome analysis did not clearly reveal the mechanism 
of the better lactose tolerance by the β-galactosidase level in the 
bifidobacteria. However, some meaningful results were derived as 
follows: 1) The proportion of several microorganisms associated with 
intestinal health tended to be differentiated between the 
165 
 
Bifidobacterium-fed groups and the untreated group, 2) The 
bifidobacterial proportion in the BGN4-G1 group tended to be 
increased compared to the other Bifidobacterium-fed groups, 3) The 
balance of SCFAs and lactate was differentiated between the 
Bifidobacterium-fed groups and the untreated group, 4) The rates 
for the change in SCFAs and lactate were grouped in a similar pattern 






















Evaluation of SOD and catalase as a food-

















Currently, the application of genetically modified (GM) 
microorganisms to food and health is strictly regulated (Pedersen et 
al., 2005). In order for GM microorganisms to be used in the food and 
health industries, host strains used for genetic engineering must have 
the GRAS (Generally recognized as safe) status, and genetic 
engineering should be done with a food-grade cloning system. A 
food-grade vector means that it contains only the DNA from 
homologous hosts or GRAS organisms and is not dependent on 
antibiotic resistance markers (Landete, 2017).  
Because lactic acid bacteria (LAB) including the Lactobacillus, 
Lactococcus, Leuconostoc, Streptococcus, Pediococcus, and 
Oenococcus species are generally considered as safe (Stiles and 
Holzapfel, 1997), there have been many studies to develop a food-
grade vector for LAB. Especially, Lactobacillus and Lactococcus 
species have been mainly used as a host for genetic engineering with 
a food-grade cloning system (Jeong et al., 2006; Li et al., 2011; Liu 
et al., 2005; Nguyen et al., 2011). Lately, there have been various 
applications of the food-grade cloning system such as expressing 
enzymes required for cheese production in LAB and using LAB as 
mucosal delivery vectors for therapeutic proteins and DNA vaccines 
168 
 
(Alvarez-Sieiro et al., 2014; Bermúdez-Humarán et al., 2011; 
Joutsjoki et al., 2002; Steidler et al., 2003; Wegmann et al., 1999).   
Because Bifidobacterium is also a representative of probiotics and 
GRAS microorganisms, it is an another appealing host for a food-
grade vector (Cano-Garrido et al., 2015). However, there are some 
limitations to actively perform genetic engineering studies with 
bifidobacteria. It should be noted that bifidobacteria have a strict 
anaerobic metabolism and a multilayered and complex cell wall 
(FISCHER et al., 1987) and restriction-modification systems making 
it difficult to use them in experiments and to achieve a high 
transformation efficiency (Park et al., 2018). Because of these 
limitations, food-grade vectors for bifidobacteria have not been 
developed yet to my knowledge. Nevertheless, because 
bifidobacteria mainly reside in the colon (De Vuyst and Leroy, 2011; 
Gibson and Roberfroid, 1995; Reuter, 2001), when applied as an oral 
vector, they will have their own value compared with Lactobacillus 
and Lactococcus, which are relatively more common in the small 
intestine (Reuter, 2001). 
Bifidobacteria are lactic acid-producing, gram-positive and obligate 
anaerobic bacteria (Wei et al., 2007). Because superoxide dismutase 
(SOD) and catalase are important components of the antioxidant 
defense system in cells against oxygen, these enzyme activities are 
deficient or absent in obligate anaerobic bacteria including 
bifidobacteria (Shimamura et al., 1992). Interestingly, several 
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studies have shown that the expression of SOD and catalase in 
bifidobacteria dramatically increases the survival rate up to 104 - 105 
fold under oxidative stress (He et al., 2012; Zuo et al., 2014). Thus, 
the aim of this study was to evaluate the feasibility of using the SOD 
and catalase genes as a selection marker for the construction of a 
food-grade vector for bifidobacteria which has not been developed 
















5.2 Materials and Methods 
 
5.2.1 Bacterial strains, plasmid DNA and culture 
conditions 
The bacterial strains and plasmids used in this study are listed in 
Table 5.1. E. coli were grown at 37℃ in Luria-Bertani (LB) medium 
(BD Difco™, Sparks, MD, USA) with shaking at 150 rpm. 
Bifidobacteria were cultured at 37℃ in Man Rogosa Sharpe (MRS) 
medium (BD Difco™) containing 0.05% L-cysteine∙HCl and 10 or 30 
μM hematin (final concentration) for some of the experiments. 
Antibiotics were used at the following concentrations: 100 μg/ml 
ampicillin (BIO BASIC INC., Markham, ON, Canada) for E. coli and 3 









Table 5.1 Bacterial strains and plasmids used in this study 
Bacterial strain Description Source or reference 
Escherichia coli DH5α  Lab stock 
Bifidobacterium bifidum BGN4  
Isolated from breast-fed infant 
feces (Park et al., 1999b) 
BGN4-SK  This work 
Plasmid   
pBES2 
7.6 kbp, ApR, CmR 
Bifidobacterium – E. coli shuttle vector 
(Park et al., 2003) 
pB-Kat 
9.2 kbp, ApR, CmR, pBES2 derivate,  
containing Pgap-Kat expression cassette 
This work 
pB-SK 
10.1 kbp, ApR, CmR, pBES2 derivate, containing Pgap-




5.2.2 DNA molecular cloning and transformation 
The target DNA fragments were amplified using TAKARA 
PrimeSTAR GXL DNA Polymerase (TAKARA, Kusatsu, Japan), and 
each primer set is listed in Table 5.2. First, the DNA fragment 
encoding the Pgap-Kat expression cassette was PCR-amplified 
from the Pgap-Kat-Phup-SOD-Thup expression cassette (Zuo et 
al., 2014) and cloned into pBES2 via AscI and FseI to construct pB-
Kat. Second, the DNA fragment encoding the Phup-SOD-Thup 
expression cassette was PCR-amplified from the Pgap-Kat-Phup-
SOD-Thup expression cassette (Zuo et al., 2014) and cloned into 
pBES2 via FseI and BstBI to construct pB-SK. All the restriction 
enzymes used in this study were purchased from NEB, Ipswich, MA, 
USA.  
Successful cloning was confirmed by nucleotide sequencing. Each 
sub-cloned vector was introduced into E. coli via heat-shock and 
the CaCl2 method and introduced into B. bifidum BGN4 by 
electroporation with the Gene Pulser Xcell Microbial Electroporation 
System (Bio-Rad, Hercules, CA, USA). The positive colonies were 
isolated, and the plasmids were purified and identified by restriction 










Sequences of primer 
Product Product information 








gap gene (glyceraldehyde 3-phosphate 
dehydrogenase) promoter in B. longum + catalase 








hup gene (histone-like protein HU) promoter in B. 
longum + SOD gene in Streptococcus thermophilus + 
hup gene terminator in B. longum 
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5.2.3 DNA manipulation 
Plasmid DNA was extracted from an Escherichia coli DH5α 
transformant harboring pBES2 or each sub-cloned vector with a 
Plasmid Purification Mini Kit (Nucleogen, Gyeonggi-do, South Korea) 
and methylated in vitro by GpC (M.CviPI) methyltransferase (NEB, 
Ipswich, MA, USA). To identify the plasmid from the B. bifidum BGN4 
transformants, plasmid DNA was extracted with a Plasmid 
Purification Mini Kit (Nucleogen) following an initial lysis step. Cells 
were resuspended in lysis buffer supplemented with lysozyme (20 
mg / ml) and incubated at 37℃ for 1 h. The extracted DNA was 
identified by sequencing and comparing the restriction patterns with 
the original plasmid DNA derived from E. coli. 
 
5.2.4 Measurement of the catalase activity 
A colorimetric assay of catalase was performed as described by 
Asru K. Sinha (Sinha, 1972).  
First, dichromate/acetic acid reagent was prepared by mixing a 5% 
solution of K2Cr2O7 with glacial acetic acid (1:3, v/v). Then, bacterial 
cells grown in MRS media supplemented with 10 μM or 30 μM 
hematin (final concentration) were harvested and resuspended in 1 
ml of 0.01 M phosphate buffer at various pH (pH 5.0 - 7.5) and mixed 
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with the assay mixture containing 4 ml of 0.8 mmol H2O2 and 5 ml of 
the above buffer. The reaction was run between 25 and 40℃. Then, 
1 ml of the reaction mixture was withdrawn and added to 2 ml of 
dichromate/acetic acid reagent. It was then heated in a boiling water 
bath for 10 min, cooled at room temperature and measured at 570 nm 
with a spectrophotometer (Model 680 Microplate reader; Bio-Rad, 
Hercules, CA, USA). 
 
5.2.5 Transformant selection under oxidative stress 
BGN4-SK and BGN4 were inoculated into MRS media containing 
0.05% L-cysteine∙HCl and 30 μM hematin (final concentration), 
respectively, and cultured for 15 h. 1 ml of the BGN4 culture was put 
into a 2 ml tube and centrifuged at 10,000 ×g for 3 min. The pellet 
was resuspended in 1 ml of 0.01 M phosphate buffer (pH 6.0) and 
added to 1 ml of BGN4-SK diluted to 10-6 with the same buffer. Next, 
30 μM Hematin (final concentration) and 4 mM H2O2 (final 
concentration) were added to the bacterial mixture (BGN4 and 
BGN4-SK), and the reaction mixture was incubated at 30℃ for 1 h. 
The reacted bacteria were centrifuged (10,000 ×g for 3 min at room 
temperature), and the harvested pellet was washed with the above 
buffer. The washed bifidobacterial cells were resuspended in 2 ml of 
the same buffer. Again, 30 μM Hematin (final concentration) and 4 
mM H2O2 (final concentration) were added to the resuspended cells, 
176 
 
and the reaction mixture was incubated at 30℃ for 1 h. After the 
centrifugation (10,000 ×g for 3 min at room temperature) and 
washing with the same buffer, the bacterial cells reacted with H2O2 
were then plated on MRS agar medium containing 30 μM Hematin 
(final concentration). All plates were incubated at 37℃ for at least 
72 h. BGN4-SK colonies were selected by the bubble reaction 
between the catalase and H2O2. A drop of 30% H2O2 was applied with 
a syringe to the edge of each colony. BGN4-SK colonies which 
express catalase evolved bubbles of oxygen and were immediately 















5.3.1 Cloning of the SOD and catalase genes, and 
heterologous expression in B. bifidum BGN4 
Given the reports that SOD and catalase are deficient or absent in 
Bifidobacterium (Shimamura et al., 1992) and the survival rate of 
Bifidobacterium in which SOD and catalase were heterologously 
expressed was drastically increased under oxidative stress (He et 
al., 2012; Zuo et al., 2014), the SOD and catalase genes were 
intended to be used as a food-grade selection marker to replace the 
antibiotic resistance genes in this study. To try this, a 
Bifidobacterium strain that strongly expresses SOD and catalase was 
necessary.  
The SOD and catalase genes to be used in this study should be 
obtained from GRAS (Generally recognized as safe) microorganisms 
to be used in the construction of a food-grade vector. I reviewed a 
study by Fanglei Zuo et al. (Zuo et al., 2014) in which SOD and 
catalase derived from lactic acid bacteria were highly expressed in 
bifidobacteria with combinations of promoters and a terminator from 
B. longum, and the recombinant had a survival rate up to 104 times 
higher than that of the wild-type in the oxidative stress caused by 
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H2O2. The Kat-SOD expression cassette used in their study was 
thankfully provided by Fanglei Zuo et al. after contacting them. 
B. bifidum BGN4 was selected as a transformation host in which SOD 
and catalase are expressed heterogeneously because this strain is 
genetically accessible among bifidobacteria (Park et al., 2018) and is 
relatively oxygen sensitive (data not shown). The SOD and catalase 
genes were amplified from the Kat-SOD expression cassette and 
subcloned into pBES2 with combinations of bifidobacterial promoters 
and a terminator and transformed into BGN4 as the host. Information 
about the genes, bifidobacterial promoters and the terminator used in 
this study is listed in Table 5.2.  
 
5.3.2 Optimization of the catalase activation conditions 
Expression of the catalase in the recombinant BGN4 (BGN4-SK) 
was confirmed by the bubble reaction with H2O2 (data not shown). 
Because the Kat-SOD expression cassette provided by Fanglei Zuo 
et al. extremely raised the survival rate of a recombinant under 
oxidative stress induced by H2O2 rather than by O2 or methyl viologen 
(Zuo et al., 2014), the BGN4-SK can be more clearly identified with 
the wild-type BGN4 under H2O2 stress. Therefore, it was necessary 
to first find the optimized conditions (such as the concentration of 
hematin added to the medium, incubation time, pH and temperature) 
at which the catalase can be expressed at the highest level in the 
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BGN4-SK. The catalase activity was measured by colorimetric 
assay designed by Asru K. Sinha (Sinha, 1972) and was expressed 
as the amount of H2O2 decomposed per min.  
Because the catalase used in this study is a heme-dependent 
catalase, in order for the catalase to become active, hematin should 
be present in the medium in which the recombinant is cultured. In 
previous studies, 10 or 30 μM hematin (final concentration) was 
added to the culture medium (Abriouel et al., 2004; An et al., 2011; 
He et al., 2012; Zuo et al., 2014); thus, I decided to determine at 
which hematin concentration the catalase activity is stronger. As a 
result, BGN4-SK showed the highest catalase activity when cultured 
in MRS media supplemented with 30 μM hematin (final 
concentration) for 15 h (Fig. 5.1.A). Incidentally, the growth rate of 
the BGN4-SK in MRS media containing hematin was compared with 
the growth rate of the wild-type BGN4 grown in MRS media without 
hematin, and no specific change was observed in the growth curve, 
although the bacterial growth rate was slightly inhibited at 30 μM 
hematin (Fig. 5.1.B). Meanwhile, the optimal temperature and pH at 
which the catalase in BGN4-SK was most highly expressed were 
also investigated and the results are shown in Fig. 5.1.C, 5.1.D. The 
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Fig. 5.1. Optimal conditions at which the catalase can be expressed 
at the highest level in the BGN4-SK 
A combination of the concentration of hematin added to the medium 
and the incubation time (A), temperature (C) and pH (D) were 
investigated. Incidentally, the growth rate of BGN4-SK in MRS media 
containing hematin was compared with the growth rate of wild-type 
BGN4 grown in MRS media without hematin (B). Catalase activity 
was measured by colorimetric assay using the principle of obtaining 
chromic acetate by reacting H2O2 with dichromate in acetic acid and 














5.3.3 Optimal H2O2 stress for transformant selection 
The optimal conditions for the catalase activity, which is crucial to 
H2O2 decomposition, were investigated before. Next, it was 
necessary to find the optimal H2O2 stress that significantly 
differentiates the survival rate between the wild-type BGN4 and 
BGN4-SK. Approximately 108 CFU/ml of BGN4 or BGN4-SK, 
cultured for 15 h in MRS media containing 30 μM of hematin (final 
concentration), were resuspended in 0.01 M phosphate buffer (pH 
6.0) and reacted for 1 h at 30℃ in H2O2 concentrations ranging from 
1.0 to 6.5 mM (final concentration). As a result, as the H2O2 
concentration increased, the BGN4-SK still maintained viable cells 
of 108 CFU/ml whereas the viable cells of BGN4 decreased to 106 
CFU/ml (Fig. 5.2.A). However, there was a limitation in that the 
viable count of the wild-type BGN4 did not decrease drastically 
enough to replace the antibiotic resistance marker. Although it was 
possible to increase H2O2 concentration even more, it was reported 
that H2O2 causes DNA degradation (Collins, 1999; Sadhu et al., 2018); 
therefore, I decided to increase the number of reactions at a mild 
H2O2 concentration rather than increase the H2O2 concentration. 
Notably, when reacted at a relatively mild H2O2 concentration of 4 
mM, the viable count of BGN4-SK still remained at 108 CFU/ml while 
that of BGN4 rapidly decreased below 104 CFU/ml from the second 
reaction (Fig. 5.2.B). It is suggested that SOD and catalase are likely 
to replace the antibiotic resistance marker because of leading the 
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Fig. 5.2 Optimal H2O2 stress for transformant selection 
Changes in survival rate of BGN4 and BGN4-SK by using various 
concentrations of H2O2 (A) or by increasing the number of reactions 























5.3.4 Possibility as a selection marker for a food-grade 
vector 
Assuming that the transformation efficiency is low, 102 CFU of 
BGN4-SK were mixed with 108 CFU of wild-type BGN4, and then, it 
was examined whether BGN4-SK is distinguishable from BGN4 
under the H2O2 stress set in this study. The selection pressure by 
H2O2 was given by repeating twice the exposure to 4 mM H2O2 in 
0.01 M phosphate buffer (pH 6.0) for 1 h at 30℃. Notably, most of 
the cells were killed and only 34 colonies remained. Bubbles emerged 
from two colonies as a result of dropping H2O2 onto the edge of each 
colony (Fig. 5.3) After the bubble-forming colonies were inoculated 
into the MRS medium, the plasmid was extracted and sequenced. The 
sequencing results were consistent with pB-SK, and there were no 
mutations in the nucleotide sequence. This means that the selection 
pressure induced by H2O2 is suitable for identifying a few 
recombinant BGN4 in the majority of wild-type BGN4 and that there 








Fig. 5.3 BGN4-SK colony forming bubble upon contact with H2O2 
When the bacterial mixture of 102 CFU of BGN4-SK and 108 CFU of 
wild-type BGN4 was treated with the set H2O2 stress, most of the 
cells were dead, and only 34 colonies remained, of which 2 colonies 
were identified as BGN4-SK. The bubbling colony in this photograph 









Reactive oxygen species (ROS) including hydrogen peroxide (H2O2), 
superoxide anion (O2
∙-), and hydroxyl radical (∙OH) are produced as 
by-products of cellular metabolism, mainly in the mitochondria. 
When ROS production overwhelms the antioxidant capacity, damage 
to cellular protein, DNA, lipid and membranes may ensue (Storz and 
Imlayt, 1999; Thannickal and Fanburg, 2000). SOD and catalase are 
typical antioxidant enzymes; thus, they are important components of 
the antioxidant defense system in cells against oxygen (Shimamura 
et al., 1992). However, these enzyme activities are deficient or 
absent in almost all obligate anaerobic bacteria including 
bifidobacteria, and in reality, neither sod nor catalase homologs are 
present in the genome of bifidobacteria (He et al., 2012; Zuo et al., 
2014). Recently, there have been studies in which SOD and catalase 
were heterogeneously expressed in bifidobacteria, and the survival 
rate of the recombinant bifidobacteria expressing them was increased 
up to 104 - 105 fold compared to the wild-type bifidobacteria under 
oxidative stress. Based on these results, the present study evaluated 
the possibility of the SOD and catalase genes as a selection marker 
for the development of a food-grade vector for bifidobacteria which 
has not been constructed to date.  
The Kat-SOD expression cassette used in this study was thankfully 
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provided by Fanglei Zuo et al. after contacting them. The catalase 
gene was derived from Lactobacillus plantarum, and the gap gene 
(glyceraldehyde 3-phosphate dehydrogenase) promoter in B. 
longum was incorporated upstream of the catalase gene. The SOD 
gene was derived from Streptococcus thermophilus, and the hup gene 
(histone-like protein HU) promoter and terminator in B. longum 
were introduced upstream and downstream of the SOD gene, 
respectively. In other words, the components of the Kat-SOD 
expression cassette, used as substitutes for antibiotic resistance 
markers in this study, were all derived from food-grade 
microorganisms. Using this expression cassette, BGN4-SK, which is 
a recombinant B. bifidum BGN4 heterologously expressing SOD and 
catalase, was developed. 
The Kat-SOD expression cassette provided by Fanglei Zuo et al. 
drastically raised the survival rate of a recombinant under oxidative 
stress induced by H2O2 rather than by O2 or methyl viologen (Zuo et 
al., 2014); thus, it was decided to use H2O2 stress to distinguish the 
BGN4-SK from the wild-type BGN4. Because catalase has a crucial 
role in the decomposition of H2O2, it was necessary to first find the 
optimal conditions at which the catalase can be expressed at the 
greatest level in the BGN4-SK. The concentration of hematin added 
to the medium, incubation time, pH and temperature, which are 
factors that maximize catalase activity in BGN4-SK, were 
established through the optimization experiments (Fig. 5.1). Next, 
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the optimal H2O2 stress was investigated to clearly distinguish the 
survival rates of the wild-type BGN4 and BGN4-SK. As a result, 
when reacted twice for 1 h at a relatively mild H2O2 concentration of 
4 mM, the viable count of BGN4-SK still remained almost unchanged 
while that of BGN4 extremely decreased by more than 99% (Fig. 5.2). 
This result implies that SOD and catalase can likely replace the 
antibiotic resistance marker because of leading the drastically 
different survival rates of BGN4 and BGN4-SK in the optimized 
conditions. In reality, when a bacterial mixture of 102 CFU of BGN4-
SK and 108 CFU of wild-type BGN4 was treated with the set H2O2 
stress, most of the cells were dead, and only 34 colonies remained, 
of which 2 colonies were identified as BGN4-SK. Collectively, the 
results suggest that the selection pressure induced by H2O2, which I 
found, are suitable for identifying a few recombinants BGN4 in the 
majority of the wild-type BGN4.  
Because it was identified that SOD and catalase can possibly act as 
a selection marker, I would like to explain the scheme of the future 
development of a food-grade vector for bifidobacteria. The first step 
should be to confirm whether selection of BGN4-SK is possible 
under the set H2O2 stress during the electroporation process. This 
experiment is currently underway in my laboratory and will proceed 
to the next step if it is successful. Because two antibiotic resistance 
genes remain in BGN4-SK, one of them should be removed by PCR, 
restriction‐enzyme digestion and ligation, and then, the target genes 
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are subcloned into the plasmid using the other antibiotic resistance 
marker when selecting recombinants in E. coli. After that, the 
remaining antibiotic resistance gene from the plasmid is removed by 
PCR, restriction‐enzyme digestion and ligation. The ligated vector is 
immediately transformed into Bifidobacterium, and the recombinant 
bifidobacteria are selected between the wild-type bifidobacteria 
under the H2O2 stress set in this study. At this time, the 
electroporation efficiency will be a key factor. Although the 
electroporation efficiency when the ligated vector was immediately 
transformed into BGN4 was reduced to 1/20 of that of the untreated 
vector in my previous study (data not shown), the electroporation 
conditions were optimized to raise the electroporation efficiency of 
BGN4 to 105 CFU/㎍ DNA, which would offset this disadvantage 
(Park et al., 2018). 
However, there are limitations in using the SOD and catalase genes 
as a selection marker for bifidobacteria. Because the reproducibility 
is not high yet, only three out of 10 trials that selected a few BGN4-
SK among the majority of wild-type BGN4 were successful. When 
treating 108 CFU of wild-type BGN4 with H2O2 stress, the final 
number of colonies was sometimes less than 100 CFU and sometimes 
more than 10,000 CFU. The experiments are not clearly controlled 
because no definite cause has been found yet. 
 Nevertheless, it is meaningful that this study searched for a 
candidate selection marker that can advance the development of a 
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food-grade vector for bifidobacteria. Because most bifidobacteria do 
not express SOD and catalase, SOD and catalase can be studied as a 
selection marker with a broad host-spectrum in bifidobacteria, if the 





































The aim of this study was to obtain a new recombinant bifidobacteria 
that highly expresses β-galactosidase by using molecular genetic 
techniques and utilize it in vitro lactose hydrolysis and in vivo 
lactose-intolerant animal experiment.  
Prior to the development of the β-galactosidase over-expressing 
bifidobacteria, a preliminary study was conducted to improve the 
electroporation-mediated transformation efficiency of bifidobacteria 
to a reproducibly high level in order to effectively introduce β-
galactosidase into bifidobacteria. As a result, when the cell wall 
weakening agent (NaCl) and cell membrane permeabilizing agent 
(Ethanol) were applied and the electrical parameter was adjusted 
from 2.5 ㎸ to 3 ㎸, the electroporation-mediated transformation 
efficiency of B. bifidum BGN4, which was a transformation host in my 
study, drastically and consistently increased from 103 to 105 CFU / 
㎍ DNA. Because the method was extensively applied to other 
Bifidobacterium species, this should allow for the advanced genetic 
manipulation of the various Bifidobacterium species in future studies. 
Returning to main study, a β-galactosidase over-expressing 
bifidobacteria strain was developed by using a heterologous gene 
from B. longum RD47 which is one of the bifidobacterial strains with 
the greatest level of β-galactosidase activity. Among the 
recombinant bifidobacteria, BGN4-G1 has the highest β-
galactosidase activity, for which the hydrolytic activity was 2.5 to 4.2 
times higher than that of BGN4 and 4.3 to 9.6 times higher than that 
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of the wild-type RD47. The β-galactosidase level of BGN4-G1 
was remarkably superior to that of any of the other 35 lactic acid 
bacteria. When commercial whole milk and BGN4-G1 were reacted, 
BGN4-G1 hydrolyzed 50% of the lactose in milk at 63 h and finally 
61% at 93 h during fermentation. This figure is about twice the 
lactose removal rate of conventional fermented milk. In the case of 
the reaction of commercial whole milk and a crude enzyme extract 
with 50 ㎍ of protein from BGN4-G1, the β-galactosidase of 
BGN4+G1 hydrolyzed half of the lactose in whole milk in 2 h, and it 
is expected to have a greater effect if the amount of crude enzyme 
extract to be used for the reaction is increased. Therefore, it is 
believed that the purification of β-galactosidase from BGN4-G1 by 
attaching a his-tag to the gene will have industrial significance, such 
as using it in the production of lactose-free milk or fermented milk. 
Probiotics administration has received attention as one of the LI 
treatments. However, because of the contradictory results of 
previous studies, no clear conclusion has been drawn as to whether 
probiotics have an effect on LI. I carefully thought that the conflicting 
results may be due to the different β-galactosidase activities of the 
probiotics strains used in each study and devised experiments using 
bifidobacteria, which have a relatively high β-galactosidase activity 
among the probiotics, with different β-galactosidase levels to 
confirm the hypothesis. Therefore, the present work evaluated in 
vivo the effect of the β-galactosidase activity of bifidobacteria on 
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LI alleviation by administering β-galactosidase reduced 
bifidobacteria, wild-type bifidobacteria and β-galactosidase over-
expressing bifidobacteria to post-weaning Balb/c mice which have 
been shown to be the LI model mice. BGN4-G1 was used as a β-
galactosidase over-expressing bifidobacteria strain and in the case 
of a β-galactosidase reduced BGN4, a BGN4 mutant (BGN4-bgr) 
showing approximately 3.2 times lower enzyme activity than that of 
the wild-type was developed by randomized mutagenesis. As a 
result, the LI alleviation effect in the BGN4-G1 administration group 
was greater than that in the lactase-treated group and even reached 
a LI-uninduced level. BGN4 administration slightly alleviated LI 
symptoms compared to BGN4-bgr administration which had no 
significant effects. This suggests that the LI alleviation effect is 
improved as the β-galactosidase activity of the bifidobacteria is 
increased. 
To explore the mechanisms for the demonstrated better lactose 
tolerance of the bifidobacteria highly expressing β-galactosidase, 
the lactose metabolism level in the small intestine was first monitored. 
Because elevated levels of plasma glucose after 30 min post-lactose 
and β-galactosidase activities of the small intestine in the 
bifidobacteria-fed groups were not significantly different compared 
to the untreated group, the mechanism of LI alleviation as the 
increases of β-galactosidase activity from the bifidobacteria is not 
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much related to the lactose metabolism in the small intestine by the 
β-galactosidase activities of the small intestine itself and the 
bacteria present there. Therefore, it was necessary to explore the 
mechanisms of LI alleviation from other aspects. Previous studies 
have reported that LI is also associated with intestinal flora. Based 
on this viewpoint, a gut microbiome analysis was performed from the 
feces of the mice fed BGN4-bgr, BGN4, BGN4-G1 or NS for two 
weeks to investigate the LI alleviation mechanism. Unfortunately, the 
gut microbiome analysis did not clearly reveal the mechanism of the 
better lactose tolerance by the β-galactosidase level in the 
bifidobacteria. However, some meaningful results were derived as 
follows: 1) The proportion of several microorganisms associated with 
intestinal health tended to be differentiated between the 
Bifidobacterium-fed groups and the untreated group, 2) The 
bifidobacterial proportion in the BGN4-G1 group tended to be 
increased compared to the other Bifidobacterium-fed groups, 3) The 
balance of SCFAs and lactate was differentiated between the 
Bifidobacterium-fed groups and the untreated group, 4) The rates 
for the change in SCFAs and lactate were grouped in a similar pattern 
in the BGN4-G1 and BGN4 groups except for the BGN4-bgr group. 
Because the BGN4-G1 exhibited a significant effect on LI alleviation, 
it is expected that BGN4-G1 can be reproduced by using a food-
grade vector for bifidobacteria, and it will be utilized as an LI 
treatment strain. I decided to construct a food-grade vector for 
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bifidobacteria and noted that bifidobacteria are obligate anaerobic 
bacteria, so they are deficient or absent in antioxidant enzyme 
activities such as SOD and catalase. The present experiment 
evaluated the possibility of SOD and catalase genes as selection 
markers for the development of food-grade vector for bifidobacteria 
that has not been constructed to date.  
First, BGN4-SK, a recombinant Bifidobacterium heterologously 
expressing food-grade SOD and catalase, was developed. In order to 
use H2O2 stress to distinguish BGN4-SK from wild-type BGN4, the 
concentration of hematin added to the medium, incubation time, pH 
and temperature which are factors that maximize catalase activity in 
BGN4-SK were established through the optimization experiment. 
Next, optimal H2O2 stress was investigated to clearly distinguish the 
survival rates of wild-type BGN4 and BGN4-SK. As a result, when 
reacted twice for 1 h at a relatively mild H2O2 concentration of 4 mM, 
the viable count of BGN4-SK still remained almost unchanged, while 
that of BGN4 extremely decreased more than 99%. It implies that 
SOD and catalase are likely to replace antibiotic resistance marker 
because of leading the drastically different survival rates of BGN4 
and BGN4-SK in the optimized conditions. In reality, when the 
bacterial mixture of 102 CFU of BGN4-SK and 108 CFU of wild-type 
BGN4 was treated with the set H2O2 stress, most of the cells were 
dead and only 34 colonies remained, of which 2 colonies were 
identified as BGN4-SK. Collectively, the results suggest that the 
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selection pressure induced by H2O2 are suitable for identifying a few 
recombinants BGN4 in the majority of wild-type BGN4. It is 
meaningful that this experiment searched for a candidate of selection 
marker that can advance the development of a food-grade vector for 
bifidobacteria. Because most bifidobacteria do not express SOD and 
catalase, SOD and catalase can be studied as a selection marker with 
a broad host-spectrum in bifidobacteria, if the selection conditions 
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본 연구는 분자 유전학적 기법을 통해 Bifidobacterium 유래 β-
galactosidase를 고발현하는 재조합 bifidobacteria를 개발하여 이를 in 
vitro lactose 가수분해 및 in vivo lactose intolerance (LI) 동물연구에 
활용해 Bifidobacterium 유래 β-galactosidase의 활용범위를 넓히는 
것을 목적으로 하였다. 또한 부수적으로, 이러한 유전자 재조합 
bifidobacteria가 장차 인체에 적용될 수 있도록 현재까지 구축되지 
않은 bifidobacteria용 food-grade vector를 위한 selection marker를 
개발하고자 하였다.  
β-galactosidase 고발현 bifidobacteria의 개발에 앞서, 
bifidobacteria에 β-galactosidase gene을 효과적으로 도입하기 위해 
bifidobacteria의 낮은 electroporation 매개 transformation 효율을 
재현성있게 높은 수준으로 개선하기 위한 사전 연구가 수행되었다. 실험 
결과, cell wall weakening agent (NaCl)와 cell membrane 
permeabilizing agent (Ethanol)를 적용하고 electrical parameter를 
2.5 ㎸에서 3 ㎸로 조정하였을 때 본 연구의 transformation host로 
사용된 B. bifidum BGN4의 transformation 효율이 103에서 105 CFU / 
㎍ DNA로 72배 높아졌다. 최적화된 방법은 다른 Bifidobacterium 
species에도 적용할 수 있었다.  
 이제 본 연구로 돌아가 Bifidobacterium 유래 β-galactosidase 
gene을 이용하여 β-galactosidase 고발현 bifidobacteria를 개발하기 
238 
 
위해, 가장 높은 수준의 β-galactosidase 활성을 갖는 
Bifidobacterium strain 중 하나인 B. longum RD47의 β-
galactosidase gene을 여러 bifidobacteria 유래 promoter들과 
조합하여 BGN4에서 발현시켰다. 개발된 재조합 bifidobacteria 중 
BGN4-G1은 BGN4보다 2.5 - 4.2 배 높고, RD47보다 4.3 - 9.6 배 
높은 β-galactosidase 활성을 나타냈다. 또한 자연에 존재하는 35개 
유산균들과 비교하였을 때에도 BGN4-G1의 효소 활성이 월등히 
뛰어났다. 시판우유와 BGN4-G1을 반응시켰을 때, BGN4-G1은 
발효되면서 기존 발효유의 약 2배에 달하는 lactose 제거율을 보였다. 
시판우유와 BGN4-G1의 crude enzyme extract를 반응시켰을 때에는 
BGN4-G1의 β-galactosidase가 2시간 동안 51%의 유당을 
가수분해하였다. 이는 50 ㎍의 단백질을 함유하는 crude enzyme 
extract를 첨가하였을 때의 결과였기 때문에 crude enzyme extract의 
양을 증가시킬 경우 더 큰 효과가 기대된다. 이들 결과들로 미루어 보아, 
his-tag을 붙여 BGN4-G1으로부터 β-galactosidase를 정제하면 
이를 lactose-free milk나 fermented milk 생산에 활용할 수 있을 
것으로 사료된다.  
Lactose intolerance (LI)는 소화관에서 β-galactosidase가 
결여되거나 부족하여 발생하는 질병으로, 세계 성인 인구의 약 75%가 
겪고 있기 때문에 공중보건관리 측면에서 전세계적인 문제로 간주된다. 
최근, Bifidobacterium species에 속하는 균주가 LI의 잠재적인 
치료제로서 주목받고 있다. 그러나 Bifidobacterium이 LI에 효과가 
있는지 없는지에 대하여 이전 연구들에서 서로 상반된 결과들이 
도출되어왔다. 우리는 이러한 상반된 결과의 원인이 실험에 사용된 균주 
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간의 β-galactosidase 활성 차이에 있다는 가설을 세웠고, 이를 
입증하기 위해 in vivo 실험을 수행하기로 하였다. 이에 따라 β-
galactosidase 저발현 bifidobacteria, wild-type bifidobacteria, β-
galactosidase 고발현 bifidobacteria를 LI model mouse로 알려진 
이유기 이후의 Balb/c mouse에 각각 투여함으로써 bifidobacteria의 
β-galactosidase 활성이 LI 완화에 미치는 영향을 확인해보았다. 이전 
실험에서 개발되었던 BGN4-G1을 β-galactosidase 고발현 
bifidobacteria로, BGN4를 wild-type bifidobacteria로 사용하였으며, 
BGN4보다 β-galactosidase 활성이 약 3.2배 낮은 BGN4 
돌연변이체인 BGN4-bgr을 개발하여 이를 β-galactosidase 저발현 
bifidobacteria로 사용하였다.  
Balb/c 마우스를 7개의 실험군으로 그룹화하였는데 각 군은 다음과 
같다. 1) wild-type BGN4 투여군, 2) BGN4-pBES2 투여군, 3) 
BGN4-bgr 투여군, 4) BGN4-G1 투여군, 5) LI만 유도된 untreated군, 
6) LI 유도 직전에 lactase가 투여된 lactase-treated군, 7) LI가 
유도되지 않은 uninduced군. 모든 mouse에 생균 용액이나 
생리식염수를 2주간 경구투여 하였으며 그 후, lactose를 투여해 
6시간동안 LI 증상을 관찰하였다. 실험 결과, BGN4-G1 투여군은 대변 
빈도와 대변의 무게가 untreated군에 비해 현저히 감소하였고 장 
운동성이 억제되었다. BGN4-G1 투여군의 LI 완화 효과는 
양성대조군으로 사용된 lactase-treated군보다 더 컸으며 심지어 
uninduced군의 수준에까지 도달하였다. 한편, BGN4 및 BGN4-bgr 
투여군의 대변 빈도와 대변의 무게는 untreated군에 비해 감소하는 
경향이 있었지만 유의한 차이는 발견되지 않았다. 장 운동성의 경우, 
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BGN4-bgr 투여군과 달리 BGN4 투여군에서 untreated군에 비해 장 
운동성이 유의적으로 억제된 결과가 나타났다. 이는 우리의 가설대로 
bifidobacteria의 β-galactosidase 활성이 높아짐에 따라 LI 
완화정도가 증가함을 시사한다. 
이전의 연구들에서 LI는 장내 미생물군집과도 연관성을 지닌다고 
보고되어왔다. 우리는 bifidobacteria의 β-galactosidase 활성에 따른 
LI 완화 기전을 이러한 관점에서 조사해보고자 BGN4-bgr, BGN4, 
BGN4-G1 또는 생리식염수를 2주간 투여한 mouse의 대변에서 장내 
미생물 분석을 실시하였다. 또한 SCFA와 lactate는 장내 미생물의 
발효산물이기 때문에 이들 mouse의 맹장 내 SCFA와 lactate의 함량을 
부수적으로 측정해보았다. 실험 결과, 다음과 같은 몇 가지 의미있는 
결과들이 도출되었다. 1) 장 건강과 관련된 몇몇 미생물들의 비율이 
bifidobacteria 투여군과 untreated군 사이에서 구분되는 경향이 있었다. 
2) BGN4-G1군에서의 Bifidobacterium 비율이 BGN4 및 BGN4-
bgr군에 비해 증가하는 경향이 나타났다. 3) SCFA와 lactate의 
balance는 bifidobacteria 투여군과 untreated군 사이에서 구분되었다. 
4) SCFA와 lactate의 변화 양상은 BGN4-bgr군을 제외한 BGN4-G1 
및 BGN4군에서 비슷한 패턴을 보였다.  
BGN4-G1이 LI 증상을 유의적으로 완화하였기 때문에, food-grade 
vector를 통해 G1을 발현하는 BGN4-G1이 개발되면 LI 완화 
균주로서 활용될 가능성이 매우 높을 것으로 기대된다. 그러나 현재까지 
bifidobacteria용 food-grade vector가 개발되지 못해 재조합 
bifidobacteria들이 인체에 적용될 수 없는 실정이다. 이에 따라, 본 
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연구에서는 bifidobacteria용 food-grade vector 개발을 위한 
selection marker로서 SOD와 catalase gene의 이용 가능성을 
평가해보았다. 먼저, lactic acid bacteria 유래의 SOD 및 catalase 
gene을 BGN4 내에서 발현시켰으며 해당 recombinant를 BGN4-SK라 
명명하였다. 그 후, BGN4-SK에서 catalase가 가장 높은 수준으로 
발현될 수 있는 최적 조건과 wild-type BGN4와 BGN4-SK의 
생존율이 명확하게 구분될 수 있는 H2O2 stress 조건을 탐색해보았다. 
이를 적용하여 108 CFU의 wild-type BGN4 내에서 102 CFU의 
BGN4-SK를 선별하는 실험을 수행해보았는데, 설정된 H2O2 stress 
하에서 대부분의 균이 죽어 오직 34개의 콜로니만이 살아남았으며 그 
중 2개의 콜로니가 sequencing 결과 BGN4-SK로 확인되었다. 이는 
H2O2 stress에 의한 selection pressure가 대다수의 wild-type BGN4 
내에서 극소수의 recombinant BGN4를 선별하는 데에 적합함을 
시사한다. 본 실험은 bifidobacteria용 food-grade vector 개발을 
진전시킬 수 있는 효과적인 selection marker 후보군을 찾았다는 데에 
의미를 지닌다.  
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